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ABSTRACT 
Dysregulated inflammatory responses are characterized by excessive release of endogenous 
pro-inflammatory molecules, danger-associated molecular patterns (DAMPs). A prototypical 
DAMP, High Mobility Group Box 1 protein (HMGB1), is primarily bound to DNA in the 
nucleus of most eukaryotic cells. However, when HMGB1 exits the cell, it acquires novel 
functions and can trigger immune activation.  
The aim of this thesis was to study the release of HMGB1, follow its fate at the site of 
inflammation and therapeutically block its activity. Multiple studies have reported that cells 
release HMGB1 in either a passive or an active manner. In order to understand the possible 
impact of cell death in inflammatory conditions, we performed well-controlled in vitro analyses 
of HMGB1 release under different cell death modes. Necrotic cells instantly released high 
levels of HMGB1, while apoptotic cells retained HMGB1 unless they advanced to secondary 
necrosis. The controlled immunogenic cell death types, such as pyroptosis and necroptosis, 
secreted HMGB1 along with other pro-inflammatory molecules in comparable or higher levels 
than cells activated with lipopolysaccharide (LPS) and interferon gamma (IFNγ). 
Next, we investigated HMGB1 proteolytic regulation at the site of inflammation. Human 
neutrophil elastase (HNE), cathepsin G (CG) and matrix metalloproteinase 3 (MMP-3), 
endoproteases present in arthritis-affected joints, cleaved HMGB1 into smaller peptides in 
vitro. While HNE and MMP-3 truncated the acidic C-terminal tail domain of HMGB1, CG 
completely degraded the protein. We showed that the C-terminal tail truncation negatively 
regulated HMGB1 binding to Toll-like receptor 2 (TLR2). Only the protein form devoid the 
acidic tail domain bound TLR2 in vitro. Thus, truncation of HMGB1 by endoproteases might 
improve its affinity to receptors. TLR2 and HMGB1 interaction did not result in cytokine 
induction. However, both full-length and truncated HMGB1 formed complexes with potent 
TLR2 ligand peptidoglycan (PGN) to potentiate the inflammatory response in peripheral blood 
mononuclear cells (PBMCs). 
Lastly, we developed a novel tool that could enable anti-HMGB1 therapy in the clinic by 
engineering a chimeric, partially humanized, monoclonal antibody (h2G7). The antibody 
displayed anti-inflammatory effects when tested in a mouse model of paracetamol-induced 
liver toxicity. Experiments with mutated variants, non-Fc receptor binding and non-
complement binding variants, of the novel antibody suggested HMGB1 neutralization as the 
mode of action. 
Taken together, results presented in my thesis increased the knowledge about HMGB1 biology 
regarding its release during immunogenic cell death, proteolytic regulation at the site of 
inflammation and interaction with its receptor TLR2. In addition, the generation of a partially 
humanized monoclonal antibody could promote the introduction of anti-HMGB1 therapy in 
the clinic. 
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1 INTRODUCTION 
 
1.1 THE IMMUNE SYSTEM 
We live in a world full of various pathogens that constantly challenge our bodies. Injured skin 
and mucosal sites enable them to enter our system. Fortunately, the immune system has evolved 
to keep us safe from the environmental hazards to ensure physiological homeostasis [2]. Not 
only does it skillfully discriminate between endogenous molecules (‘self’) and molecules 
derived from pathogens (‘non-self’), but it also participates in tissue repair and removal of 
dying cells [3]. Importantly, danger signals released by host cells under sterile conditions, as a 
result of cell death or stress, serve as potential triggers of immune activation [4]. Most of the 
immune processes occur smoothly and we are not aware of the molecular challenges that we 
are facing on a daily basis. However, certain illnesses and novel pathogens can compromise 
the immune system. Complex defense mechanisms are engaged to promote health and restore 
homeostasis. 
1.1.1 Innate and adaptive immunity 
The immune system consists of a complex network of specialized cells that is conventionally 
divided into two overlapping mechanisms to destroy pathogens: the innate immune system and 
the adaptive immune system [5, 6]. The innate system is evolutionarily older and serves as the 
first line of defense against infections and sterile injury, i.e. hazards of non-microbial origin 
[7]. It is rapidly activated and has the ability to recognize pathogens and products of injured 
cells. The innate immune cells actively scan the body and activate biochemical defense 
mechanisms upon danger recognition. However, these innate immune responses are not very 
specific and only activate the same mechanisms when subjected to repeated threats [8]. 
 
On the other hand, the adaptive immune system is slower to respond but much more efficient 
in the termination of the danger [9]. It is characterized by high specificity to a great variety of 
targets and the ability to create memory towards detected hazards. The defense mechanisms 
are fine-tuned towards previously encountered threats. Thus, the adaptive immune system 
responds more effectively and precisely compared to the innate immune system. All cells of 
the immune system secrete soluble proteins that activate, regulate and coordinate its many 
activities. It is evolutionarily beneficial for the body to have two interconnected systems for 
danger recognition and elimination as the innate and adaptive immune systems complement 
and communicate with each other ensuring proper immune function [10]. While this thesis 
focuses mainly on the mechanisms within the innate immune system, it is important to 
remember about its cooperation with the adaptive immunity. 
1.1.2 Cells and receptors of the innate immune system 
The innate immune system has passive and active components. The passive part consists of 
physical and chemical barriers as well as circulating proteins that protect the body against 
infections. The physical barrier of our innate immune system is visible to the naked eye as it 
consists of epithelial cells (i.e. skin) and epithelial mucosa that provide the first line of defense 
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against the harmful environment [11]. Anti-microbial molecules produced by the epithelium 
provide the chemical barrier [12]. Another passive part of innate immunity is a system of 
circulating plasma proteins termed the complement system [13]. These elements can directly 
bind to pathogens and alarm the immune system by recruiting innate immune cells or inducing 
direct lysis of the pathogen [14].  
Cells compose the active component of the innate immune system. While the tissue-resident 
scavenger cells such as macrophages, granulocytes and dendritic cells (DCs) are the first ones 
to respond to danger in their proximity, the most efficient tissue-resident cells to fight against 
infections are professional phagocytes that actively engulf extracellular content [15]. These 
include neutrophils, monocytes, macrophages, mast cells and DCs, which are armed with 
pattern recognition receptors (PRRs) on their surfaces [16, 17]. Receptors are specialized 
protein molecules capable of sensing and responding to chemical signals received from outside 
the cell. PRRs have the ability to engage classes of molecules rather than individual ligands. 
Thus, they detect diverse molecular motifs such as microbial nucleic acids, lipoproteins and 
carbohydrates, which are collectively known as pathogen-associated molecular patterns 
(PAMPs). Many of the PRRs can also detect motifs released from injured cells, damage-
associated molecular pattern (DAMP) molecules [18, 19]. Thus, the molecular sensing and 
response to tissue injury resembles mechanisms involved in the elimination of exogenous 
pathogens.  
Four families of PRRs currently exist: Toll-like receptors (TLRs), C-type lectin receptors 
(CLRs), NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs) [1, 20]. Members of the 
TLR family are major PRRs in cells. The discovery of TLRs was an important breakthrough 
for immunology research and the scientific community recognized that by awarding the 2011 
Nobel Prize to Jules Hoffmann and Bruce Beutler [21]. TLRs are type I transmembrane 
proteins containing leucine-rich repeats (LRRs) that recognize PAMPs and certain DAMPs 
both in the extracellular environment (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 on cell 
surface) and intracellularly (TLR3, TLR7, TLR8, TLR9 and TLR10 in endosomes) [22]. C-
type lectin receptors (CLRs), primarily expressed on membrane of macrophages and DCs, 
often collaborate with TLRs during an immune response [23]. PRRs also include two classes 
of cytoplasmic receptors: NLRs and RLRs. NLRs are best known for their ability to activate 
NF-κB leading to production and secretion of pro-inflammatory molecules. The NLR family 
members NOD2 and NLRP3 have received considerable attention as mutations in these 
proteins are linked to inflammatory disease [24]. Lastly, signaling through the RLRs activates 
intracellular pro-inflammatory processes in response to viral and bacterial nucleic acids in the 
cytoplasm. The PPR examples and their PAMP and DAMP ligands are illustrated in Figure 1. 
Twenty-five years ago, Alan Shaw and colleagues described a novel scavenger receptor and 
called it receptor for advanced glycation end products (RAGE) [25]. It was recognized that 
besides binding advanced glycated proteins, RAGE detects a class of ligands through a 
common structural motif [26]. Interaction of RAGE on leukocytes or endothelial cells with its 
ligands results in the transcription of pro-inflammatory molecules and inflammatory cell 
recruitment [27]. All of the aforementioned characteristics classify RAGE as a PRR. There is, 
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however, one striking difference between RAGE and other PRRs, as there are no known 
exogenous ligands for RAGE. 
 
1.1.3 The immune response 
The body needs to regulate the activation of the immune system very tightly. A complex 
network of firmly regulated mechanisms accomplish this by utilizing numerous checkpoints 
controlling immune activation and ensuring that leukocytes are recruited and activated only in 
response to foreign invaders and dead tissues. Systemic activation of leukocytes could have 
detrimental consequences due to the potential cytotoxic properties of the immune cells.  
The initiatory steps of immune responses involve activation of PRRs, which then assemble 
large complexes in order to transmit the danger signal. Next, the activated signaling cascades 
trigger the release of factors promoting recruitment of leukocytes to the region of infection. 
Some infections are easily cleared due to prompt phagocytosis by the tissue-resident cells, 
while others cause immune activation and lead to inflammation. 
 
1.2 CELL DEATH AND IMMUNE ACTIVATION 
Perhaps the most evident consequence of host-pathogen interactions is cell death. Although it 
was described as early as in the 19th century, it is only recently that cell death has been 
recognized as an important player at the site of inflammation [28, 29]. Depending on the 
mechanisms involved, cell death can contribute to tissue homeostasis or inflammation and 
disease pathogenesis. Host cell death may impair normal organ function and lead to associated 
signs of disease. 
Figure 1. Pattern recognition receptors (PRRs).  PRRs are localized on the cell surface as well as in 
endosomes and cytosol. TLR4 is a membrane bound receptor and its ligands include LPS (PAMP) and 
HMGB1 (DAMP). TLR9 is expressed in endosome, where it recognizes non-methylated CpG motifs of 
bacterial and viral DNA (PAMPs) and extracellular genomic/mitochondrial DNA (DAMPs). NLRP3, a 
NOD-like receptor, binds bacterial muramyl dipeptide (PAMP) and extracellular ATP (DAMP) in the 
cytosol. More information about PRRs and their ligands and be found in review by Takeuchi et al. [1].     
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1.2.1 Homeostatic cell death 
Every day billions of aged or faulty cells die which the body complements by generating the 
same number of new cells. The immune system does not react to such homeostatic cell 
clearance as it mainly proceeds by a controlled silent process called apoptosis [30]. The word 
apoptosis originates from Greek and denotes a “falling off” which refers to leaves falling from 
the tree in the fall [31]. This is an imaginative way to describe a harmless process of removing 
individual components of an organism without destruction or damage to the organism itself. 
This mode of cell death involves mechanisms leading to elimination of harmful and old cells. 
Apoptotic cells are engulfed by macrophages and successful absorption of the dying cells 
ensures that no intracellular components are released into the extracellular environment [32]. 
Apoptosis is often referred to as a type of a programmed cell death since it is either a genetically 
determined elimination of cells during normal development or a highly controlled cell 
disintegration during the immune response [33]. The mechanisms of apoptosis are highly 
complex, involving an ATP-dependent cascade of molecular events and the regulation of over 
thousands of proteins [34]. 
Apoptosis can be triggered by a variety of physiological agents signaling intrinsically as a 
response to damaged DNA or extrinsically through death receptors on the cell surface. The 
intrinsic pathway involves the Bcl-2 protein family members that can stimulate the release of 
cytochrome c from mitochondria. Hence, it is often referred to as the mitochondrial apoptotic 
pathway. Once cytochrome c relocates to cytosol, it binds to Apaf-1 to form a protein complex 
named the apoptosome, which in turn leads to the execution of apoptosis [35]. The extrinsic 
apoptosis pathway is triggered by death receptors of the tumor necrosis factor (TNF) family. 
Those membrane-bound proteins contain death domains, which transmit the death signal from 
the cell surface to the intracellular signaling pathways. The extrinsic and intrinsic pathways are 
linked so that molecules in one pathway can influence the other [36]. Both pathways are 
orchestrated by a distinct molecular mechanism led by cysteine proteases (caspases) acting in 
cascades and merging on the same execution pathway. This terminal pathway culminates in 
the cleavage of caspase 3 and the disposal of fragmented DNA and proteins in apoptotic bodies 
expressing ligands for phagocytic cell receptors [37].  
Although apoptosis is considered a homeostatic cell death, overwhelming apoptosis or 
inefficient apoptotic cell clearance can also contribute to immune activation. When apoptotic 
cells are not efficiently engulfed by phagocytes, they undergo secondary necrosis and release 
intracellular immune-stimulatory materials including DAMPs. Such clearance deficiencies are 
major contributors to the development of autoimmune inflammation in systemic lupus 
erythematosus (SLE) [38].  
1.2.2 Immunogenic cell death 
Cell death that is not developmentally programmed is a sign of stress, injury or infection and 
is linked to tissue damage and disease pathogenesis. Contrary to homeostatic apoptosis, 
infected cells can die in an immunogenic manner (Figure 2). The classic example of a non-
programmed cell death is necrosis, which denotes cell response to damage [39]. During 
necrosis, the sudden cell membrane rupture and loss of structural integrity results in passive 
release of intracellular components including cytosolic enzyme lactate dehydrogenase (LDH) 
and DAMPs into the extracellular space [40]. Necrotic cell debris acts as a potent trigger for 
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inflammation [29]. Despite the widespread use of the apoptosis-versus-necrosis paradigm, 
there is an increasing awareness of the complexity of processes prior to immunogenic death. 
Multiple immunogenic cell death modes have been described and recently classified as either 
necrosis or stress-induced cell death [41]. The latter is often referred to as regulated necrosis 
due to the distinct mechanisms that lead to cell membrane disintegration. Multiple cell death 
modes that occur during inflammation or infection are programmed or regulated by gene 
products. Stress-induced cell death includes several cell death modes such as necroptosis, 
pyroptosis and cell death associated with the release of extracellular traps, which is described 
as NETosis in neutrophils.  
The term “necroptosis” was introduced in 2005 to indicate a new pathway of programmed 
necrosis [42]. Since then, plenty of molecules and processes have been characterized as 
initiators of necroptosis including toll-like receptors and the apoptosis-activating death 
receptors. However, there are multiple differences between apoptosis and necroptosis. Firstly, 
necroptosis does not proceed by the caspase-dependent intracellular signaling routes. 
Therefore, it can overpower apoptotic pathways in situations where energy supplies are limited 
such as ischemia. Secondly, execution of this cell death mode involves the loss of membrane 
integrity, release of DAMPs and a proinflammatory response [43, 44]. Although, the molecular 
pathways involved in necroptosis are still not fully understood, they depend on the kinase 
activity of receptor-interacting protein 1 (RIP1) and RIP3 with mixed lineage kinase domain-
like pseudokinase (MLKL), a substrate of RIP1 kinase. Necroptosis contributes to disease 
pathogenesis and plays a central role in myocardial infarction, stroke, drug-induced liver 
injury and ischemia–reperfusion injury [45-47]. Blocking necroptosis has shown promising 
therapeutic results in the treatment of multiple animal disease models, such as myocardial 
ischemia-reperfusion injury and ethanol-induced liver injury. The blockade is possible through 
suppression of RIP1 kinase activity by a specific inhibitor, Necrostatin-1 (Nec-1) [48, 49].  
Certain hazards induce the production of immature forms of inflammatory mediators and the 
formation of inflammasomes, which in turn leads to a cell death called pyroptosis. The term 
pyroptosis was introduced in 2001 to describe the process of pro-inflammatory chemical 
signals bursting out of a host cell (“pyro” means fire in Greek) [50]. Released DAMPs are 
sensed by Nucleotide-binding oligomerization domain, Leucine rich Repeat and Pyrin domain 
containing (NLRP) protein family that are the core parts of a protein complex responsible for 
innate immunity activation of the inflammasome. The mechanism of the NLRP3 
inflammasome activation is well described in macrophages and involves recruitment and 
subsequent cleavage of pro-caspase 1 to its active form caspase 1 [51-53]. Caspase 1 in its turn 
processes the pro-forms of the inflammatory mediators IL-1β and IL-18 that are subsequently 
released as mature inflammatory mediators [54]. Caspase‐1 also cleaves gasdermin D leading 
to colloid‐osmotic lysis and release of cytoplasmic contents including DAMPs and LDH [55]. 
Therefore, pyroptosis not only plays a protective role in the host response to infection but it 
can also promote pathogenic inflammation. It is associated with strong inflammatory 
conditions driven by Salmonella-infected macrophages, or during gout and rarer 
autoinflammatory conditions [56]. 
Another interesting immunogenic type of cell death can be observed in a few cell types 
including neutrophils. Since neutrophils are the most abundant leukocytes in the human body 
and they are the first cells migrating to the infected site, their deaths can significantly affect the 
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host immune system. Those short-lived cells have classically been known to die by apoptosis. 
However, a neutrophil-specific death leading to the release of extracellular traps (NETs) was 
discovered in 1996. NETs are composed of chromatin fibrils and antimicrobial proteins that 
can kill invading pathogens. Moreover, NETosis can be involved in noninfectious 
inflammatory events and has the ability to amplify the immune response. The main component 
of NETs is DNA. Nucleic acid can be sensed by some PRRs, such as endosomal TLR9 of 
plasmacytoid dendritic cells (pDCs) and monocytes. Activation of these receptors leads to the 
synthesis of pro-inflammatory mediators. 
It is important to remember that cell death modes are not mutually exclusive and can co-exist 
independently or act in concert during an inflammatory response. Immunogenic cell death 
pathways, however, can drive the pathogenesis of certain disease phases. For example, 
inflammation during gout is propagated in a positive-feedback loop by inflammatory mediators 
released by pyroptotic macrophages [57]. In addition, the same triggers can induce different 
death pathways depending on the cell type as well as the intensity and persistence of the 
stimulus. At low doses, a variety of pathogenic stimuli such as hypoxia and cytotoxic anticancer 
drugs can induce apoptosis but these same stimuli result in secondary necrosis at higher doses 
[58, 59].   
 
Figure 2. Myeloid cell undergoing homeostatic and immunogenic modes of cell death. Apoptosis is a 
homeostatic type of cell death that can be induced by extrinsic or intrinsic pathways. Death receptor activation 
and downstream signaling marks the extrinsic pathway of apoptosis. The intrinsic pathway, on the other hand, is 
characterized by cytochrome c release and apoptosome formation. Both pathways are executed by ATP- dependent 
apoptotic effector caspases 3 and 7 and lead to the formation of apoptotic bodies. In contrast, necrosis is an abrupt 
cell membrane disintegration and results in the release of the intracellular contents. Pyroptosis is a stress-induced 
cell death mode characterized by inflammasome-mediated cytokine release. Similarly to extrinsic pathway of 
apoptosis, necroptosis is initiated by death receptors. However, the lack of ATP, e.g. due to starvation, directs 
cells to proceed with RIP1/3 pathway instead of energy-dependent apoptotic caspase cascade. NETosis is a cell 
death type characterized with rapid release of NETs containing intracellular molecules. 
  7 
1.3 INFLAMMATION  
Ancient Greek scholars, such as Hippocrates, were among the first to report the reaction by the 
body to injury or stress. In AD 25, a Roman encyclopedist, Aulus Cornelius Celsus, 
summarized symptoms of the immune response as heat, redness, swelling, pain and loss of 
function [60]. Those are the cardinal signs of inflammation, the protective host response of the 
innate immune system to the injury or stress. The molecular events leading to systemic 
inflammation manifestations described by Celsus have been extensively studied over centuries 
leading to the identification of immune cells, specialized mediators and changes in blood 
vessels, needed to eliminate the initial cause of cell injury and to initiate the process of repair. 
Nowadays, we also understand that the cardinal signs of inflammation illustrate only the 
initiation phase of the inflammation. Equally important to the induction of inflammation is its 
resolution. Inflammation does not resolve in a passive way but as a result of active processes. 
Two thousand years after Celsus described symptoms of inflammation, Charles Serhan 
identified molecules that mediate the resolution of inflammation and promote homeostasis 
[61]. Regulated inflammation with both induction and resolution phases occur during acute 
inflammation (e.g. a burn). Without inflammation, the infection would go unchecked and lead 
to a more serious condition. Prolonged inflammation, however, can also be harmful [62]. When 
the resolution phase of inflammation fails, inflammatory cells and mediators continue to 
promote tissue destruction. This condition is called chronic inflammation and is a major cause 
of complex human autoimmune inflammatory pathologies such as arthritis [63]. My thesis 
work focuses on such dysregulated inflammation (Figure 3).  
Figure 3. Acute vs. dysregulated inflammation.  PAMPs and DAMPs that are sensed by PRRs on cells can 
initiate the inflammatory response. Activation of PRRs results in expansion of the inflammatory response by 
chemokine and cytokine production. Chemokines recruit circulating cells to the site of injury and cytokines 
activate cells to remove the danger and initiate resolution of inflammation.  
In case of acute inflammation, such as a burn, the process follows the course of regulated inflammation and 
leads to repair and homeostasis. Dysregulated inflammation proceeds by different patterns: 1. overwhelming 
systemic expansion of inflammation, such as septic shock, 2. Uncontrolled local expansion of inflammation 
induced by mediators released from injured cell, such as drug-induced liver injury, 3. chronic inflammation 
where the balance between the expansion and resolution phase is not achieved, such as arthritis. 
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1.3.1 Pathogenesis of inflammatory diseases  
Inflammation can be either local or systemic. However, this is not a binary process and local 
inflammation can lead to complex systemic effects in multiple human diseases. Here, the 
mechanisms involved in pathogenesis of arthritis and drug-induced liver injury (DILI) were 
studied. 
DILI is the leading cause for acute liver failure in the Western world and results from injury to 
resident liver cells [64]. Although the injury is local, DILI represents a broad spectrum of liver 
manifestations including acute or chronic hepatitis and a critical condition called acute liver 
failure (Figure 4a). DILI often occurs due to cytotoxic hepatocyte death after an overdose of 
acetaminophen (APAP), either in an intended suicidal attempt or by and accidental harmful 
drug combination [65, 66]. The pathogenesis of APAP overdose has been well characterized 
and develops when a small proportion of the drug gets metabolized to a reactive metabolite, N-
acetyl-p-benzo-quinoneimine (NAPQI) [67]. The toxic by-product acts both as a strong 
electrophile and as an oxidant that bind intracellular molecules and induce mitochondrial 
dysfunction. Downstream events lead to activation of the immunogenic cell death pathways 
and subsequent DAMPs release. The presence of pro-inflammatory molecules in the blood (IL-
6 and IL-8) indicates the involvement of inflammatory pathways [68]. APAP overdose is 
problematic to treat due to a lack of reliable biomarkers and a short window of opportunity for 
patient treatment with the classical medication, N-acetylcysteine (NAC) [69, 70]. Since many 
patients do not reach the emergency room within the therapeutic time bracket, there is a great 
need to identify new therapy targets and more stable biomarkers than cytokines and liver 
enzymes. One promising marker is miR-122; miRNA accounting for 75 % of the total miRNA 
in the liver [71]. DAMPs and other inflammatory molecules released from dying liver cells 
could also serve as potential biomarkers.  
Chronic inflammatory systemic diseases like arthritis develop over a span of years and once 
self-tolerance is broken, symptoms of local inflammatory events in the joints appear. While the 
etiology of arthritis is not fully understood, it involves environmental factors that trigger 
disease in genetically susceptible individuals, which is about 1% of the human population [72]. 
The disease manifests itself by chronic joint inflammation leading to joint disability both in 
adults (rheumatoid arthritis, RA) and children (juvenile idiopathic arthritis, JIA). The 
synovium, tissue surface in the joint, thickens so that the patient’s mobility is disturbed. 
Circulating immune cells, such as monocytes and neutrophils, infiltrate the joint tissue and 
execute inflammatory processes by secreting specialized molecules (Figure 4b). An excess of 
synovial fluid accumulates and causes swelling of the joint. Interestingly, neutrophils are also 
present in synovial fluid of arthritis patients. The inflamed synovium invades adjacent cartilage 
and promotes articular degradation. Activated immune cells release pro-inflammatory 
mediators and regulatory enzymes as well as DAMPs. RA has a quite well defined 
inflammatory profile with autoantibodies to immunoglobulin G and anti-citrullinated protein 
antibodies (ACPAs) [73]. Due to disease heterogeneity, arthritis treatment is often crafted to 
the patient. Standard treatment involves nonsteroidal anti-inflammatory drugs (NSAIDs) 
complemented by inflammatory mediator blockers, such as anti-TNF agents [74, 75]. 
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1.3.2 Soluble mediators in inflammation: PAMPs, DAMPs and cytokines 
Activated, injured and dying cells present their status to the immune system utilizing several 
classes of soluble mediators. Initiatory steps of inflammation are triggered by agents either of 
exogenous or endogenous origin, PAMPs and DAMPs, which lead to immune activation and 
inflammatory signal propagation by cytokines. 
Lipopolysaccharide (LPS) is a bacterial endotoxin coming from the outer membrane of Gram-
negative bacteria. This is the most studied PAMP and is recognized by TLR4 [76]. LPS is an 
extremely potent immune activator and its systemic presence can lead to a critical inflammatory 
condition called septic shock. Another example of PAMP is peptidoglycan, a polymer forming 
the cell wall of Gram-positive bacteria, specifically recognized by TLR2.  
1.3.3 Endogenous mediators of inflammation 
Endogenous molecules can also initiate inflammatory responses. In 1994, Polly Matzinger 
concluded that the immune system is so concerned with the consequence of infection or injury 
that it can stop discriminating between ‘self’ and ‘non-self’[77]. She called this phenomenon 
“The Danger Theory” and defined DAMPs, the endogenous initiators of inflammation. 
Importantly, this class of soluble mediators comprises diverse group of molecules that have 
non-immune functions within the cell and become danger signals only when they reach the 
extracellular space. Stimulated leukocytes and epithelia actively secrete DAMPs while necrotic 
cells passively release them. All cell types in the body express certain DAMPs, such as heat 
Figure 4. Inflammatory diseases. a) Drug-induced liver injury due to APAP overdose results in cytotoxic 
hepatocyte death and leads to a broad spectrum of liver manifestations including acute or chronic hepatitis and a 
critical condition called acute liver failure. b) Arthritis develops gradually and leads to thickening of the synovium 
and tissue infiltration by activated circulating immune cells. 
a) b) 
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shock proteins (HSPs) and High Mobility Group Box 1 (HMGB1) protein. Moreover, S100 
family members expressed in phagocytes are also considered DAMPs. Once those proteins 
enter the extracellular space, they are capable of binding TLRs and RAGE thanks to their 
hydrophobic parts revealed upon release [78]. DAMPs do not only include nuclear, cytosolic 
and extracellular matrix proteins but also organic molecules and metabolites such as ATP, uric 
acid crystals and nucleic acids. However, only the DAMP proteins were categorized as 
alarmins by Joost Oppenheim ten years after “The Danger Theory” was published [79]. 
Alarmins promote the activation of innate immune cells and the recruitment and activation of 
antigen-presenting cells, but also promote tissue repair. Due to their pro-inflammatory 
activities, alarmins may serve as useful diagnostic and prognostic biomarkers in inflammatory 
disorders. They may also serve as therapeutic targets. 
After TLR binding, DAMPs or PAMPs can utilize the intracellular adaptor protein MyD88 and 
signal downstream leading to activation of NF-κB, which is a nuclear transcription factor [80]. 
The NF-κB activation leads to cytokine and chemokine transcription in macrophages, mast 
cells and endothelial cells. These small proteins are the basic units of the body’s 
immunomodulatory language so that several different types of cells can secrete a given 
cytokine. Once secreted, cytokines act on the target cell and relay the pro- or anti-inflammatory 
message by binding to specific receptors. Cytokines amplify and direct the inflammation to 
combat the stress mainly by leukocyte recruitment. Historically, many cytokines are called 
interleukins (ILs) due to the belief that they could only carry information between leukocytes. 
Although a bit misleading, the name interleukins remained. Some cytokines are produced in a 
mature form while others require further processing within the cell. For example, IL-1β is 
synthesized in a pro-form and requires inflammasome and subsequent caspase-1 cleavage [81]. 
The major cytokines in acute inflammation are TNF, IL-1β, IL-6 and a group of 
chemoattractant cytokines called chemokines [82]. Acute-phase cytokines act locally and 
usually over a short range to activate endothelial cells and local tissue leukocytes, create 
positive feedback loops to amplify cytokine release and chemokine recruitment. They also 
increase vascular permeability allowing immune cell migration from circulatory system into 
tissue. Although TNF, IL-6 and IL-1β are secreted at sites of inflammation, they may enter the 
circulation and act at distant sites to induce the systemic acute-phase reaction that is often 
ssociated with infection and inflammatory diseases [83]. Measuring systemic levels of 
cytokines n patients provides good insight into the status of an inflammatory disease. 
Importantly, pro-inflammatory cytokine blockade turned out to be a successful therapy for 
dampening dysregulated inflammatory response in several diseases 
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1.3.4 Regulation of soluble mediators 
Since excessive immune activation could be harmful for the body, a dynamic and tight 
regulation of soluble mediators exists ensuring that inflammatory processes are run in a 
controlled manner. Certain molecules that counteract the pro-inflammatory events are already 
produced alongside inflammatory mediators during the induction phase of inflammation. Such 
anti-inflammatory molecules can ameliorate the immune response by modulating production, 
function and activation of pro-inflammatory agents. Thanks to tight regulation of the immune 
response, tissue damage is limited and the defense mechanisms turn into healing processes. 
Multiple systems have evolved in order to control and downregulate pro-inflammatory 
processes before the resolution of inflammation takes place.  
Table 1: Key endogenous mediators of inflammation.  
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Certain anti-inflammatory cytokines and specific cytokine inhibitors mediate suppression of 
inflammatory responses. The most prominent anti-inflammatory cytokines are IL-10 and TGF-
β1, which are potent inhibitors and downregulators of pro-inflammatory cytokines produced 
by macrophages and cells of the adaptive immune system [84]. However, many cytokines have 
both pro- and anti-inflammatory properties. IL-6 is an example of a cytokine with dual 
functions. Although IL-6 was described as a pro-inflammatory mediator of acute inflammation 
in the chapter above, it is known to downregulate pro-inflammatory cytokines by promoting 
the synthesis of Interleukin-1 receptor antagonist (IL-1ra) and release of soluble TNF receptor, 
which dilutes TNF inflammatory activities [85]. Cytokines act as a double-edged sword and 
the net outcome of their actions depends on factors such as the timing of cytokine release, the 
availability of receptor and local milieu. 
During the course of chronic inflammatory disease, recruited and activated neutrophils release 
serine proteases upon degranulation [86]. Two common neutrophil enzymes, elastase and 
cathepsin G, degrade the TNF precursor into biologically inactive fragments [87]. Moreover, 
serine proteases can downregulate immune responses by cleaving essential receptors on the 
surface of both adaptive and innate immune cells. For example, neutrophil elastase cleaves 
receptor for IL-8 on the surface of neutrophils, thereby preventing neutrophil activation and 
migration to the synovium [87, 88]. Other downregulatory mechanisms seen in inflammatory 
disease are reduced PRRs density on cell surface and receptor blockade by non-inflammatory 
agents. Actually, inducing natural IL-1ra shows therapeutic effects in RA treatment [89].  
More research is needed to understand the downregulation of DAMPs. There are no known 
anti-inflammatory agents produced by cells that could counteract DAMPs in a similar way to 
how anti-inflammatory cytokines work. However, some regulatory mechanisms seen in 
cytokine downregulation also have effects on DAMPs. One of such similarity is the processing 
by proteases. For example, mast cell chymase and neutrophil cathepsin G can cleave and 
activate alarmin IL-33 [90-92]. DAMPs are also subject to soluble scavenger receptor binding 
which limits their pro-inflammatory capacity. 
Many inflammatory mediators are subject to post-translational modifications (PTMs). Those 
covalent chemical modifications of amino acids occur after protein synthesis and provide a 
plethora of mechanisms for regulation of proteins produced by the cell [93, 94]. Protein 
function can be affected by PTMs so that molecules can gain or lose pro-inflammatory 
activities. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) post-
translationally modify many thiol-containing redox-sensitive molecules, thus playing an 
important role in inflammatory disease pathogenesis.  
 
 
 
 
 
  13 
2 HMGB1: A PROTOTYPICAL DAMP 
 
As discussed in the previous chapter (§1.3.2), DAMPs, also known as alarmins, are non-
microbial pro-inflammatory molecules released from dying or stressed cells. The highly 
conserved nuclear protein, HMGB1, acts as a prototypical alarmin once it exits the cell [95].  
HMGB1 was first isolated and described in 1973 by Graham Goodwin and Ernest Johns [96]. 
Back then, the researchers only recognized it as a member of the chromatin-binding group of 
molecules, which migrated fast during electrophoresis. As HMGB1 is ubiquitously expressed 
by almost all eukaryotic cells, it was not too surprising that it turned out to be the most abundant 
protein in the discovered protein group. All four members of the isolated protein family contain 
HMG box domains that are DNA-binding motifs characterized by three α-helices [97]. 
HMGB1 contains 215 amino acids that form two subsequent HMG box domains (boxes A and 
B) followed by a C-terminal tail domain (Figure 5a). The consecutive boxes contain a high 
number of positively charged lysine residues while the C-terminus is formed by a stretch of 30 
continuous negatively charged glutamic and aspartic acid residues. This unique bipolar charge 
of the molecule prompted some researchers name the protein “amphoterin” [98]. As the protein 
started to be researched more extensively over the past 20 years, the scientific community 
decided to prevent confusion and call the protein HMGB1 [99]. 
The first time HMGB1 was reported as a DAMP was in 1999, when the group led by Kevin 
Tracey discovered that it was present the in blood of mice during endotoxemia.  It was proposed 
as a late mediator of lethality as mice showed increased serum levels of HMGB1 between 8 to 
32 hours after endotoxin exposure [100]. Discovery of the nuclear protein as a pro-
inflammatory factor in circulation was a breakthrough in HMGB1-related research and 
encouraged the scientists to study HMGB1 properties as a DAMP. 
c) 
b) 
a) 
Figure 5. HMGB1 structure and redox isoforms. a) HMGB1 consists of three domains: DNA-binding boxes A and 
B, and an acidic C-terminal tail. Two lysine-rich NLS regions are located within the structure. Fully reduced HMGB1 
has thiol groups attached to cysteine residues at positions 23, 45 and 106 (C23, C45, C106) of the 215 amino acid 
sequence. The fully reduced HMGB1 isoform is localized in the cell nucleus or extracellularly in the reducing 
environment where it promotes chemotaxis.  b) Disulfide HMGB1 has a disulfide bond between C23 and C45 while 
C106 has a thiol group attached. This isoform has a cytokine-inducing function. c) When the cysteine residues become 
oxidized HMGB1 loses its immunogenic functions. 
 14 
2.1 THE GENERATION AND RELEASE OF EXTRACELLULAR HMGB1 
As mentioned above, HMGB1 is a highly abundant nuclear protein. A single cell is estimated 
to contain approximately 10 million HMGB1 molecules [101]. The box domains of HMGB1 
bind to the minor groove of DNA and bend its structure, which results in enhanced accessibility 
of DNA to regulatory elements including transcription factors and nucleosomes [102]. Two 
lysine-rich nuclear localization sequences (NLSs) are present within the protein structure 
whose unmodified form determines nuclear localization of HMGB1 [103]. Lysine residues are 
subject to a PTM called acetylation. If no multiple acetyl groups are introduced to NLSs, 
HMGB1 intranuclear localization and function is favored. However, hyperacetylated NLS1 
and NLS2 regions promote HMGB1 relocation to the cytosol by preventing nuclear reentry 
[104]. Cytosolic HMGB1 has been demonstrated to be an autophagy regulator and nucleic acid 
sensor. Hyperacetylation is associated with active HMGB1 secretion. This process is regulated 
enzymatically by the activity of histone acetyl transferases (HATs) and histone deacetylases 
(HDACs). Studies show that HDAC inhibition promotes cytoplasmic translocation and the 
release of HMGB1 [105].  
HMGB1 can be released in a passive or an active manner. The major source of extracellular 
HMGB1 is through necrosis. This rapid form of cell death is typically followed by 
inflammatory reactions due to passive release of HMGB1 and other alarmins. Necrotic cell 
debris are potent triggers of inflammation and necrotic cells lacking HMGB1 display greatly 
impaired pro-inflammatory properties [106]. HMGB1 is also actively secreted during 
pyroptosis and further escalates the inflammatory reactions [107-109]. The active secretion of 
HMGB1 is not fully understood since the protein lacks a classic leader peptide and its secretion 
is thus not routed through the classical protein secretion pathway via endoplasmic reticulum – 
Golgi. 
Studies suggest that activated monocytes, macrophages, DCs and other immune cells actively 
discharge HMGB1 via two-step mechanism. First process requires HMGB1 translocation to 
the cytoplasm dependent on hyperacetylation of NLS sites as a result of JAK–STAT pathway- 
activation [110]. The JAK-STAT pathway is the principal intercellular signaling mechanism 
that can be activated by a variety of molecules, such as or IFNγ [111]. Hyperacetylated 
HMGB1 accumulate in the cytosol and becomes a subject of different secretory mechanisms. 
It has been shown that cytoplasmic HMGB1 can be packed into and released by secretory 
vesicles, similarly to members of the IL-1 family, in response to inflammatory stimuli [112]. 
Hyperacetylation of lysines was observed in HMGB1 released during pyroptosis as a 
consequence of NLRP3 and NLRC4 inflammasome activation [52, 113]. On the contrary, 
passive release of HMGB1 does not require NLS acetylation. Therefore, HMGB1 that is 
released rapidly due to disruption of cell membrane is not hyperacetylated. When HMGB1 is 
passively released during cell death or secreted by activated cells into the extracellular milieu, 
the molecule acquires a novel function to serve as a powerful mediator of inflammation [100, 
114]. 
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2.2 PRO-INFLAMMATORY FUNCTIONS OF HMGB1 
There are thousands of scientific publications regarding HMGB1 functions and most of them 
focus on the pathogenic functions of the molecule. My thesis goes along with this trend and 
focuses on understanding the molecular events regarding the release and extracellular 
regulation of HMGB1 pro-inflammatory activities. 
2.2.1 Impact of PTMs on HMGB1 function 
Upon release to the extracellular space, HMGB1 acts as a prototypical DAMP and can initiate 
and perpetuate inflammatory responses by binding to different receptors. Studies using high-
resolution mass spectroscopy and NMR have identified different functional isoforms of 
HMGB1 depending on the redox status of three conserved cysteine residues C23, C45 and 
C106 [115-117]. The cysteine thiolate represents a potent nucleophile containing a sulfur 
atom that can form bonds to another sulfur atom or to hydrogen, nitrogen, oxygen and carbon 
atoms [118]. 
The biochemical form of HMGB1 determines the receptor binding capabilities of the molecule. 
Certain isoforms are recognized as pro-inflammatory, while others have no known immune 
function. The reducing environment within the cells under physiological conditions promotes 
thiol cysteine side-chains of HMGB1. This redox isoform is commonly denoted “fully reduced 
HMGB1” (“HMGB1C23hC45hC106h”, Figure 5a). However, oxidation of the cysteine thiol 
groups at positions 23 and 45 facilitates the formation of a disulfide bridge resulting in a minor 
change in protein conformation but, strikingly, a major change in biological activity [119]. If 
the cysteine at position 106 remains in its thiol form while a disulfide bond forms between 
cysteines 23 and 45, HMGB1 function also changes. Such “disulfide HMGB1”-mediated 
signaling leads to NF-κB activation and proinflammatory cytokine release [115, 116]. In order 
to clarify the biochemical form of the cytokine-inducing HMGB1, a more specific 
nomenclature has been proposed: “HMGB1C23-C45C106h” or more simply “HMGB1C23-
C45” (Figure 5b) [118]. In order to understand the relationship between different redox 
isoforms and put them into the context of inflammatory disease, a real-time kinetics study of 
HMGB1 isoform stability was performed with In Situ Protein NMR Spectroscopy [120]. The 
study concluded that the fully reduced HMGB1 half-life is regulated by the nature of the 
extracellular environment. While the half-life of fully reduced HMGB1 was only about 17 
minutes in human serum and saliva, it extended to 3 hours in prostate cancer cell culture 
medium [120]. Considering ROS involvement is a typical phenomenon in an inflammatory 
disease, the pro-inflammatory isoforms of HMGB1 should instead be considered a molecule 
with a short half-life. One could speculate that the detection of endogenous disulfide HMGB1 
implies an active production of such isoform. When HMGB1 undergoes further oxidation due 
to an increased oxidative environment, all three cysteines become oxidized to an irreversible 
sulfonyl form. This “sulfonyl HMGB1” (“HMGB1C23soC45soC106so”, Figure 5c) has not 
been shown to have any pro-immunogenic function [121]. Interestingly, this terminal oxidation 
of HMGB1 has been recorded in the resolution phase of inflammation and may be a natural 
occurring mechanism in downregulating pro-inflammatory activities of HMGB1 [115]. 
Sulfonyl HMGB1 has also been reported to increase cytotoxicity of chemotherapeutic agents 
in cancer therapy by inducing apoptosis via the mitochondrial pathway [122].  
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While the functional activity of HMGB1 seems to be solely dependent on its cysteine redox 
states, the extent of inflammation in disease is more strongly correlated with the acetylation 
status of the NLSs than the total levels of HMGB1 [104, 123]. We have recently shown by LC-
MS/MS analysis that the levels of HMGB1 released into the synovial fluid of juvenile 
idiopathic patients strongly correlates with acetylation of NLS2 and that NLS acetylation 
correlates with the pro-immunogenic forms of HMGB1 [124]. However, it remains unclear 
whether HMGB1 is secreted in its intranuclear fully reduced form and undergoes functional 
shifts in the extracellular space, or whether these shifts occur within the cells before it is 
released. 
2.2.2 HMGB1 binding PRRs 
One way to assess immune mediator’s function is by identifying the receptors it employs. To 
date, 14 different receptors have been described as targets of the extracellular HMGB1 [114, 
125]. None of the identified receptors is unique to HMGB1. However, PRR systems were 
studied more in detail with regard to HMGB1 signaling and are considered the dominant 
receptors for HMGB1: TLR4 and RAGE.  
 RAGE 
The first receptor that was identified as HMGB1 binder was RAGE [126]. There are two 
RAGE-binding sites within HMGB1 structure: within aa23-50 and 150-183 [125]. The latter 
one was the first reported binding site for RAGE and resulted in neurite outgrowth in the fetal 
mouse brain, while the other binding site was identified recently and its binding to RAGE 
reversed apoptosis-induced tolerance in dendritic cells [127, 128]. HMGB1 interaction with 
RAGE results in NF-κB activation followed by induction of chemotaxis in many cell types 
including dendritic cells and neutrophils [129, 130]. TLR4 deficient macrophages do not 
produce cytokines when activated by highly purified HMGB1 of any redox isoform [119]. As 
RAGE is normally expressed at low levels on the cell surface, the degree of RAGE expression 
needed for cytokine induction is still unknown. Alternatively, HMGB1-dependent cytokine 
release may not result from the direct RAGE-activated intracellular signal cascades. Research 
teams lead by Jie Fan and Timothy Billiar at the University of Pittsburgh recently showed that 
HMGB1 can be endocytosed via RAGE and later translocated into lysosomes in macrophages. 
After lysosomal rupture HMGB1 entered cytoplasm and led to pyroptosome formation, 
caspase-1 activation and cytokine production [131, 132]. 
 HMGB1 and TLRs 
Germline encoded TLRs are major PRRs in cells and several of them are recognizing and 
responding to HMGB1. Out of the suggested TLRs, the interaction between HMGB1 and 
TLR4 is best understood and is highly dependent on the redox state of HMGB1. Disulfide 
HMGB1 activates TLR4 in presence of MD-2 on the cell surface [133]. HMGB1 signaling 
through TLR4/MD-2 complex results in initiation of intracellular signaling events such as 
activation of ERK1/2, JNK, IKKα, IKKβ and p38 signaling pathways. The intracellular 
reactions culminate in NF‐κB transcription factor translocation and subsequent pro-
inflammatory cytokine production. Interestingly, recombinant box B, which contains the 
cytokine-inducing domain of HMGB1, also binds to TLR4 [119]. The disulfide HMGB1 form 
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can induce long-lasting hypersensitivity in muse arthritis models in a TLR4 dependent manner 
[134] 
While the binding of HMGB1 to TLR4 has been extensively studied, binding to other TLRs 
has also been reported. However, neither the redox state of HMGB1 nor any other molecular 
requirements are presently known for other Toll-like receptor interactions. HMGB1 is a ligand 
for TLR2 and TLR5 and their interaction leads to activation of pro-inflammatory pathways. 
Similar to HMGB1-TLR4 interaction, binding of HMGB1 to TLR2 results in intracellular 
events leading to NF‐κB activation [135]. Studies utilizing cell line overexpressing TLR2 
confirmed the NF‐κB-dependent signaling by IL-8 production. However, TLR2 blockade did 
not prevent TNF release by HMGB1 neither in stimulated primary macrophages nor whole 
blood cultures [119]. Thus, HMGB1 interaction with TLR2 is not considered as cytokine 
inducing. This was also demonstrated in this thesis work focused on the physical interaction 
between TLR2 and HMGB1 ([136], Paper III). TLR5 has only recently been identified as 
HMGB1 receptor. HMGB1 binding to TLR5 initiates NF-κB signaling pathway activation in 
a MyD88-dependent manner. The pro-inflammatory processes due to HMGB1 interaction with 
TLR5 result in allodynia in rats [137]. 
2.2.3 HMGB1: a partner in crime 
HMGB1 acts in synergy with other pro-inflammatory mediators and as a partner molecule 
signals through a broader range of receptors than on its own. This unique feature of HMGB1 
has created confusion over the years regarding the biological functions of the molecule and its 
pathological role in disease. Nowadays, HMGB1 researchers need to verify that they work with 
a pure protein but for many years the possibility of HMGB1 complex formation with pro-
inflammatory agents was overlooked. Independently of its redox isoform, HMGB1 enhances 
pro-inflammatory functions of exogenous or endogenous pro-inflammatory molecules. 
Let us start with the receptors mentioned in the previous chapter. A prototypical PAMP, LPS, 
signals through TLR4 [138]. LPS binding to the receptor is facilitated by LPS-binding protein 
(LBP), which transfers LPS to CD14 to initiate TLR4-mediated pro-inflammatory response. 
HMGB1 plays a similar role to LBP by transferring LPS to CD14, which results in an enhanced 
LPS-mediated inflammation [139]. HMGB1 has two high-affinity binding sites for LPS 
enabling complex formation [140]. Stimulation with preformed HMGB1-LPS complexes 
induces a 100-fold stronger response than stimulation with comparable levels of LPS alone 
[141]. The potent cytokine-inducing function of HMGB1-LPS complex has been demonstrated 
in multiple studies in vitro [141-144]. An exciting novel discovery regarding HMGB1-LPS 
complex function came out last year from a big joint study between Ben Lu’s and Timothy 
Billar’s labs. Researchers showed that the LPS-HMGB1 complex can be internalized via 
RAGE and lead to caspase-11-dependent lethality in sepsis [145].  
HMGB1 pairs up also with other PAMPs and DAMPs to signal through TLRs. PGN from 
bacteria and Pam3CSK4, a synthetic triacylated lipopeptide, are exogenous TLR2 ligands that 
show enhanced stimulatory effect when complexed with HMGB1. Endogenous TLR2 ligands 
include nucleosomes, which can also for complexes with HMGB1 to stimulate cytokine 
production from primary macrophages in a TLR2-dependent manner [146]. TLR2 deficient 
mice produce less anti‐dsDNA and anti‐histone antibodies than wild type mice [147]. 
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Nucleosomes bound to HMGB1 break immunological tolerance to double-stranded DNA and 
induce production of cytokines [146]. In 2007 an endosomal receptor, TLR9, was identified as 
a receptor for HMGB1 in a complex with DNA and same year was the direct binding of 
HMGB1 to TLR9 confirmed by immunoprecipitation [148, 149]. HMGB1-DNA complexes 
are recognized by RAGE and then transferred to endosomal TLR9 receptors mediating 
enhanced IFNγ production in plasmacytoid DCs and B lymphocytes [148]. 
When HMGB1 acts as a partner molecule, it can support signaling through few other receptors 
besides PRRs. It enhances the activity IL-1α and IL-1β and stromal cell–derived factor-1 (SDF-
1/CXCL12) through their receptors [143, 150, 151]. While cytokine-inducing effects of pro-
inflammatory molecule are enhanced by HMGB1 independently of its redox state, only fully 
reduced HMGB1 can interact with CXCL12 to act as a chemoattractant by activation of the 
CXCR4  [151-153]. In addition, interaction between fully reduced HMGB1 and RAGE induces 
upregulation of CXCL12 expression [154]. Thus, extracellular HMGB1 can play distinct roles 
at the same time: induce cytokine production on its own through TLR4 if in disulfide form or 
complex with LPS and recruit inflammatory cells to damaged tissue if in fully reduced form 
and bound to CXCL12. Interestingly, HMGB1-CXCL12 complex can also play a beneficial 
role by promoting tissue healing after solid organ injury [154]. Known PRRs of HMGB1 are 
presented in Figure 6 below.  
 
 
 
 
Figure 6. HMGB1 binding PRRs alone or in complex with other molecules. HMGB1 is a ligand for TLR2, TLR4, 
TLR5 and RAGE. In addition, HMGB1 forms complexes to enhance other receptor-specific ligands, such as boosting 
LPS signaling via TLR4. HMGB1 and LPS complexes are internalized via RAGE, allowing HMGB1 to interact with 
endosomal and cytosolic PRRs. 
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2.2.4 Downregulation of HMGB1 
As many other soluble mediators of inflammation, HMGB1 is a subject for regulation that 
limits its pro-inflammatory activities. Several endogenous molecules bind and neutralize 
extracellular HMGB1. One of such agents is haptoglobin, a protein that binds free hemoglobin 
in blood plasma and directs it towards removal by the reticuloendothelial system. It has been 
shown that haptoglobin also forms complexes with fully reduced and disulfide HMGB1 
(although with a lower affinity than hemoglobin) [155]. The haptoglobin-HMGB1 complexes 
are taken up by macrophages via the hemoglobin scavenger receptor CD163 and induce the 
production of anti-inflammatory agents, such as heme oxygenase-1 and IL-10. Moreover, 
plasma level of soluble CD163 is increased in a large spectrum of acute and chronic 
inflammatory disorders, further suggesting HMGB1 downregulation by haptoglobin and 
CD163 as an anti-inflammatory mechanism [155, 156].  
There is another interesting relationship between HMGB1 and macrophages regarding the 
functional regulation. While disulfide HMGB1 directs monocyte differentiation towards pro-
inflammatory (M1) macrophage phenotype, a complement protein C1q modulates HMGB1 
effects on cell differentiation towards anti-inflammatory M2-like macrophages [157]. 24-hour 
exposure of monocytes to both HMGB1 and C1q leads to expression of classical M2 
macrophage markers, such as Mer, PD-L1, IL-10 and CD163. However, C1q binding cannot 
completely cease pro-inflammatory functions of HMGB1 as it only mediates the reaction via 
RAGE inhibition while having no effect on HMGB1-TLR4 signaling [157].  
As mentioned in §1.3.4, inflammatory mediators can also be downregulated by soluble 
receptors released to circulation. Such receptors bind extracellular HMGB1 and dilute its 
signaling. RAGE, which is a specific HMGB1 receptor, also exists in a soluble form lacking 
C-terminal and transmembrane domain. Soluble RAGE (sRAGE, an extracellular truncated 
form of RAGE that acts as a decoy receptor) disrupts HMGB1-RAGE signaling, thus 
dampening HMGB1 pro-inflammatory functions [158, 159]. Rheumatoid arthritis patients 
display low levels of sRAGE both in the blood and synovial fluid allowing pathogenic 
signaling of HMGB1 via RAGE [160]. 
One study reported that CD24, a membrane-bound protein modulating growth and 
differentiation signals received by mature granulocytes and B cells, also negatively regulates 
extracellular HMGB1 activity and inhibits NF-κB activation. Accordingly, CD24-deficient 
mice exhibit increased susceptibility to DAMPs. The process of HMGB1 downregulation by 
CD24 is partially mediated through Siglec G in mice or Siglec 10 in humans [161]. 
An interesting mechanism of HMGB1 downregulation utilizes activities of both an anti-
inflammatory molecule and a protease. HMGB1 is degraded by thrombomodulin, an 
endothelial anticoagulant cofactor that promotes thrombin-mediated formation of activated 
protein C [162, 163]. Thrombomodulin binds and sequesters HMGB1 utilizing the N-terminal 
domain, which results in the proteolytic cleavage of HMGB1 by thrombin [162, 164]. 
Lastly, the NMR study of HMGB1 oxidation mentioned earlier (§2.2.1) also provided kinetic 
information about the clearance of the alarmin due to protease activities in extracellular fluids. 
Researchers noticed reduction of total HMGB1 but could not distinguish any smaller HMGB1 
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peptides. They concluded that once cleavage occurs, HMGB1 molecules become highly 
susceptible to complete digestion by extracellular proteases to an amino acid level [120]. 
 
2.3 PATHOLOGICAL ROLE OF HMGB1 IN DISEASE 
Forming complexes with other pro-inflammatory mediators and signaling through different 
receptors enables HMGB1 to contribute to disease pathogenesis in multiple ways. The specific 
role HMGB1 plays in disease mechanisms depends on its release mode and the environment it 
enters. Factors such as the total amount of the alarmin, its redox state, availability of receptors 
and binding partners shape the net outcome of HMGB1 signaling.  
HMGB1 signaling through TLR4 is mostly associated with negative effects. It has been 
implicated in the pathogenesis of ischemia/reperfusion injury of multiple organ systems 
including kidney, brain, heart, and liver [165-170]. Studies with experimental disease animal 
models of human disease also suggest a role for the HMGB1-TLR4 axis in lung inflammation 
and injury, inflammation following traumatic injury, as well as seizure generation and 
perpetuation in epilepsy [171-173]. HMGB1 is also a major player driving pathogenesis of 
sepsis and trauma, the leading causes of patient death in the Western world. Its negative role 
is also prominent in arthritis and DILI, which is described more in detail in the following 
chapters. 
Interestingly, HMGB1 acts as a double-edged sword in cancer. The pro-inflammatory 
HMGB1-TLR4 signaling is crucial for effective responses to chemo-radiation in established 
tumors [174]. On the other hand, some studies suggest that HMGB1 can also contribute to 
immunosuppressive cancer microenvironment by association with receptor TIM-3 on DCs. 
TIM-3 actively competes with nucleic acids to bind the A box of HMGB1, thereby inhibiting 
antitumor efficacy of DNA vaccines and chemotherapy [175, 176]. 
Despite many deleterious activities of HMGB1 in the inflammatory disorders, there are also 
some positive effects of the alarmin. As explained in §2.2.3, fully reduced HMGB1 forms a 
heterocomplex with CXCL12 and acts via CXCR4 as an immunostimulatory chemoattractant. 
However, it also promotes tissue healing and regeneration. Injection of HMGB1 accelerates 
skeletal, hematopoietic, muscle and liver regeneration by acting on resident and infiltrating 
cells [154, 177]. Stem cells play a key role in the healing reactions as upon HMGB1-CXCL12 
complex stimulation, quiescent stem cells that express CXCR4 transition from G0 to GAlert [154, 
178]. Such primed stem cells respond to the activating factors released upon injury and readily 
enter the cell cycle, thereby promoting tissue repair.  
2.3.1 HMGB1 during DILI 
Liver cells, hepatocytes, express high levels of HMGB1. Thus, injury to the liver can cause 
massive HMGB1-induced inflammation. The mechanisms of HMGB1 release and 
inflammatory functions in liver diseases have been extensively studied in liver diseases, such 
as drug-induced liver injury (DILI). Actually, DILI is believed to be the best-characterized 
HMGB1-dependent condition in preclinical animal models and in patients. 
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As explained in §1.3.1 DILI can occur when paracetamol/APAP, a commonly used painkiller, 
is overdosed. The increase in drug dose or reduction of antioxidants in the liver increases the 
amount of a toxic by-product of paracetamol metabolism, NAPQI. The excess of metabolite is 
highly toxic for hepatocytes as it reacts with free cysteine residues, causes mitochondrial 
dysregulation, tissue hypoxia and decreased hepatic metabolism. Thus, the consequence of 
NAPQI challenge is cell function impairment followed by a combination of apoptotic and 
necrotic cell death in the liver. Necrotic hepatocytes passively release multiple DAMPs 
including the intranuclear fully reduced HMGB1, a ligand for RAGE. Moreover, the hypoxic 
environment is associated with increased expression of HMGB1 binding partner, CXCL12. 
The HMGB1-CXCL12 complex induces leukocyte recruitment to the liver via CXCR4 [152]. 
The leukocyte activation and influx into the liver results in a new phase of HMGB1 release. 
Now, immunogenic isoforms of HMGB1 are secreted by the activated immune cells and can 
intensify the inflammatory processes in the liver by signaling via TLR4 and RAGE. Animal 
studies with conditional knockout of HMGB1 indicate that the second wave of HMGB1 release 
is responsible for DILI-associated lethal inflammation [100, 167]. 
While more studies are needed to verify whether the mechanistic results from preclinical 
studies could be translated to the clinical setting, HMGB1 has already been proved as a useful 
biomarker for paracetamol-induced acute liver injury (ALI), an acute type of DILI. 
Interestingly, serum level of HMGB1 measured within 8 hours of drug overdose outperforms 
the commonly used liver injury marker alanine aminotransferase (ALT) as a predictor of ALI 
development [179]. This is extremely useful information for clinicians as it enables them to 
identify the first stage of APAP hepatotoxicity and adjust the patient treatment. Clinical 
symptoms of toxic drug ingestion typically present only in the third stage of the condition. Late 
patient arrival in the clinics is arguably the most challenging and devastating feature of DILI. 
It is during stage III of APAP hepatoxicity, when the maximal liver injury occurs leading to 
multi-organ failure [180]. This stage has the highest risk of mortality. Early biomarkers of DILI 
are of great need in order to recognize the pathological processes early and prevent patient 
mortality. HMGB1 is a good candidate for being such biomarker but not the perfect one. There 
are some disadvantages of the measurement of serum HMGB1 from APAP-overdose patients. 
Even though HMGB1 is expressed in high levels by hepatocytes, it is not specific for the liver 
cells. In fact, any dying or stressed cell in the body can release HMGB1. Therefore, measuring 
HMGB1 systematically can be misleading when the patient suffers from underlying 
inflammatory conditions. HMGB1 could be an informative biomarker when combined with 
liver-specific markers such as ALT and miR-122. There is also hope that HMGB1 isoform 
measurement could improve HMGB1 value as an early DILI biomarker. 
2.3.2 HMGB1 in arthritis 
HMGB1 also contributes to chronic inflammatory conditions, such as arthritis. While the cause 
of arthritis is not fully understood, the inflammatory reactions associated with the disease 
symptoms have been quite well defined. Probably the most striking evidence for HMGB1 as a 
key mediator driving the pro-inflammatory mechanisms in arthritis comes from animal studies. 
In a rat experimental arthritis model, HMGB1 was detected in all nuclear, cytoplasmic and 
extracellular compartments of synovial tissue while it was restrained in the nucleus in tissue 
of healthy rodents [181]. Moreover, researchers at Sahlgrenska University Hospital in 
Göteborg showed that intra-articular injection of recombinant HMGB1 into mouse joints 
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induced long-lasting destructive arthritis in healthy rodents [182]. They also complemented the 
study with detailed in vitro experiments showing HMGB1-induced activation of macrophages. 
Recently, another important discovery regarding HMGB1-driven disease symptoms came from 
animal studies. Signaling of disulfide HMGB1 through TLR4 induced long-lasting pain 
hypersensitivity associated with arthritis in mice [134]. 
Strong evidence of HMGB1 role in arthritis come from clinical studies. Examination of 
synovial fluid and synovial tissue biopsies indicate abnormal expression of HMGB1 in 
inflamed joints of RA and JIA patients. In fact, HMGB1 in the pannus tissue has been 
associated with the aggressive and destructive synovitis at the cartilage–bone interface [183]. 
Ex vivo assays with patient cells give insight in HMGB1 pro-inflammatory activities and the 
pathogenic mechanisms in arthritis. Endogenous HMGB1 interacts with TLR4 in synovial 
fluid extracted from arthritis patients most likely contributing to the severe disease profile 
[119]. Moreover, monocytes from RA patients require only a low concentration of HMGB1 to 
enhance CXCL12-induced migration indicating activity of HMGB1-CXCL12 heterocomplex 
is chronic inflammation associated with arthritis [184].  
My research group has a special interest in understanding the mechanisms of JIA, arthritis in 
children. Our studies confirm that HMGB1 is significantly increased in the inflamed joints of 
JIA patients directly reflecting the extent of local inflammation. While other inflammatory 
mediators such as S100 proteins, IL-6 and IL-8 are increased at the disease onset, HMGB1 
levels remain apparent during the active disease independent of disease duration [185]. Alarmin 
extracted from synovial fluid of JIA patients displays a pro-inflammatory profile. HMGB1 
redox isoforms demonstrate mainly cytokine-inducing or chemotactic functions while the 
hyperacetylated form of the HMGB1 indicates its active secretion. Mono-methylation at lysine 
residue in box A of HMGB1 reveals its neutrophil origin [124].  
While the analysis of tissue and fluid at the site of inflammation gives a valuable insight into 
disease mechanisms, molecules detectable in circulation are preferable as candidates for 
disease biomarkers. HMGB1 levels are significantly elevated in serum of RA patients and 
correlate with the disease activity score DAS-28 [186]. Therefore, HMGB1 measured in the 
joint provides detailed information about disease mechanism while blood measurement of 
HMGB1 is a general indicator of disease activity. 
2.3.3 Dampening inflammation through anti-HMGB1 therapy 
While HMGB1 can serve as diagnostic, prognostic and predictive biomarker of different 
inflammatory diseases, efforts are made to also evaluate it as a therapeutic target. Currently, 
there is no anti-HMGB1 therapy in clinics. However, targeting HMGB1 in experimental 
models shows promising results and highlights the need of introducing anti-HMGB1 therapy 
for patients suffering from conditions with inflammatory components. Different types of 
biologics have been developed in order to inhibit HMGB1 specifically, including antibodies, 
recombinant peptides of HMGB1 fragments and soluble receptors. 
Several treatment strategies for targeting HMGB1 in DILI have been tested in mice by either 
inhibiting its release or function (or both). A classic method for targeting a molecule in 
circulation is developing recombinant antibody against it. This approach has been successful 
both with polyclonal and monoclonal antibodies. APAP- challenged mice have significantly 
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decreased serum HMGB1 concentrations and reduced gut bacterial translocation by 85% after 
treatment with polyclonal HMGB1 antibody [187]. Even more exciting results come from 
studies with monoclonal antibody against aa 53-63 of HMGB1, so called m2G7. Besides 
improving mouse survival, antibody reduced the liver injury size and APAP- induced 
inflammation [133]. Other promising treatment options targeting HMGB1 release in DILI 
include chemical interventions with ethyl pyruvate and therapy with naturally derived 
compounds such as glycyrrhizin [188, 189]. Currently, small peptides are receiving 
considerable attention as an alternative strategy to target HMGB1. A tetrameric peptide FSSE 
(named P5779) blocks HMGB1 interaction with myeloid differentiation factor 2 (MD-2), 
thereby preventing disulfide HMGB1 signaling through TLR4. P5779 shows therapeutic 
effects by reducing elevation of hepatic serum enzymes and TNF, liver necrosis, and by 
improving survival in mouse model of DILI [133].  
HMGB1 blockade has also been successful in arthritis models. Multiple experimental studies 
demonstrate improved outcome after treatment with HMGB1-specific antagonists. Systemic 
administration of polyclonal neutralizing HMGB1 antibody and recombinant box A in 
collagen‐induced arthritis (CIA) and a spontaneous chronic, destructive polyarthritis 
significantly reduced the mean arthritis score, the disease‐induced weight loss, and protected 
against the devastating destruction of cartilage and bone. Importantly, HMGB1 suppressed 
arthritis associated inflammation in rodents [190, 191]. The monoclonal HMGB1 antibody, 
m2g7, was also tested in those two mouse arthritis models. Therapeutic anti-HMGB1 
intervention significantly ameliorated the clinical disease course and partially prevented joint 
destruction, as demonstrated by histological examination [192]. Monoclonal HMGB1 antibody 
has also reduced pain hypersensitivity associated with arthritis [134].  
Whilst the mechanism of action for certain drugs used in the treatment of arthritis patients is 
not fully understood, studies suggest that they may target HMGB1. Methotrexate (MTX), a 
standard disease-modifying antirheumatic drug, is a good example. The majority of patients 
responding to MTX experience less pain, joint swelling and lower disease activity overall 
[193]. Recent studies show that MTX binds to HMGB1 and prevents its association with 
RAGE. In vitro studies on murine macrophage-like cells confirmed that MTX inhibit TNF 
release dependent on specific RAGE stimulation with HMGB1. Therefore, HMGB1 inhibition 
is part of the mechanism of action for the anti-inflammatory effect of MTX [194]. Another 
example is gold sodium thiomalate (GST), a gold compound that has been administered as 
injections to treat RA for many years. Although GST is not a popular treatment any more, its 
inhibitory effect on HMGB1 is noteworthy. Activated macrophages do not release 
HMGB1after GST stimulation as GST interferes with intracellular HMGB1 transport 
mechanisms [195]. 
Currently, more therapeutic tools against HMGB1 are being developed and tested in different 
experimental disease models. They include administration of recombinant HMGB1 
downregulators, such as haptoglobin, thrombomodulin and soluble RAGE. As these molecules 
have a broad set of substrates, monoclonal HMGB1 antibody and small recombinant molecules 
may a better approach to target HMGB1 specifically.  
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2.4 BIG CHALLENGES IN HMGB1 FIELD 
While experimental studies show very promising results, there are still numerous barriers to 
cross to bring anti-HMGB1 therapy to clinics. Ubiquitous expression and complex biology of 
HMGB1 have been discouraging pharmaceutical companies to examine HMGB1 as a target in 
disease. Therefore, there is a big need to understand HMGB1 biology in terms of its release, 
structure and PTMs. The academic research centers have taken on the responsibility to expand 
knowledge. 
The most desired goal for anti-HMGB1 therapy would be a straightforward method to identify 
and inhibit pro-inflammatory isoforms of HMGB1. Unfortunately, the isoform identification is 
currently dependent on a time consuming and expensive mass spectrometry analysis. There are 
only a few laboratories worldwide capable of measuring HMGB1 isoforms and the central one 
has been dealing with scientific misconduct. Several recently published studies based on 
collaboration with this lab need verification. Lastly, there is also limited knowledge regarding 
total levels of HMGB1 in the healthy individuals [196]. Lifestyle factors, such as smoking, 
alcohol drinking and Western-style diet can potentially increase the extracellular systemic 
HMGB1 levels [197, 198]. It is therefore unclear what levels of the alarmin are not necessarily 
alarming. All these factors decelerate progress in clinical HMGB1 research. 
Addressing the big challenges in HMGB1 field requires a good collaboration of dedicated 
researchers all over the world and can take long years of hard work. My efforts to expand 
knowledge about HMGB1 biology and its role in inflammation resulted in the experimental 
studies described in the following chapters and attached to this thesis. While the presented work 
is a just a small puzzle in the big HMGB1 field, it is the small pieces that make the big picture. 
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3 AIMS OF THE THESIS 
 
It is well established that HMGB1 plays a major role as a DAMP in the pathogenesis of 
inflammatory diseases. However, it is not fully understood how the protein exerts its functions 
and how it is regulated in the extracellular space. The aim of this thesis was to characterize 
HMGB1 release patterns from immune cells and its pro-inflammatory activities. Moreover, we 
set out to investigate endogenous down-regulatory mechanisms controlling HMGB1 
extracellular functions. 
Blockade of HMGB1 has shown promising results in multiple animal disease models. In order 
to evaluate the HMGB1 potential as a therapeutic target and facilitate anti-HMGB1 therapy 
development in clinical setting, we decided to develop a novel therapeutic tool and test it in an 
established animal disease model. 
 
The specific aims of this thesis are to: 
• Understand how and to which extent monocytic cells release HMGB1 during immune 
activation and different modes of cell death 
 
• Elucidate whether HMGB1 is a substrate for proteases associated with chronic 
inflammatory conditions; and whether such processing results in formation of 
functional fragments and /or HMGB1 functional downregulation 
 
• Investigate HMGB1 interaction with TLR2 and determine the functional outcome of 
the receptor binding 
 
• Develop a humanized anti-HMGB1 antibody as a potential therapeutic option and test 
its effect in an inflammatory disease model 
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4 METHODOLOGICAL CONSIDERATIONS 
 
While the methods used in each study are listed in the Material and Methods sections of the 
publications and manuscripts attached to this thesis, my reasoning behind their selection and 
concerns regarding their use are discussed below. One should remember that all methods have 
advantages and flaws. The researcher has the responsibility to select procedures and materials 
appropriate for testing the scientific hypothesis. Despite constant advances in molecular 
biology tools and methods, the reality of basic research in academia is that one often needs to 
focus on the resources available in lab. 
 
4.1 RECOMBINANT PROTEIN PRODUCTION 
My studies relied heavily on recombinant HMGB1 expressed and purified from Escherichia 
coli (E. coli). The standard protocol for recombinant protein production involves the 
construction of an expression plasmid followed by a pilot experiment to assess the yield and 
solubility of the target protein. Successful completion of the optimization steps is followed by 
large-scale protein expression and purification. Experienced researchers in our lab constructed 
the plasmids used in these studies before my experiments commenced. For publication 
purposes, our HMGB1 proteins contained either a calmodulin-binding protein (CBP; rat 
HMGB1) or a cleavable 6-residue polyhistidine (HIS; human HMGB1) tag at the N-terminus 
of the protein. Importantly, both of these tags have no known effect on HMGB1 function [199].  
In my studies, I have used both rat and human HMGB1 proteins. HMGB1 is a highly conserved 
protein, which exhibits 99% sequence homology across species. There are only two amino 
acids differences between rodent and human HMGB1: D189E and E202D. Considering that 
these substitutions occur within the C-terminal tail of the protein, and that glutamic and aspartic 
acid residues have similar properties, the slight sequence difference is highly unlikely to 
influence protein function. However, other factors could affect the activity of lab-produced 
HMGB1. These include purity, mismatches in expression and PTMs. 
As discussed in the introduction of this thesis (§2.2.3), HMGB1 forms highly active pro-
inflammatory complexes by binding both LPS and DNA. Endotoxin and DNA contamination 
can result in misjudgment of HMGB1’s cytokine-inducing activity, a common problem that 
affected the field in the early years of HMGB1 research. When producing the recombinant 
proteins used in this these experiments, LPS was eliminated using Triton-X114 purification 
and bacterial DNA was removed by DNase I treatment. To confirm that these removal methods 
were efficient, endotoxin and DNA levels were measured using the limulus amoebocyte lysate 
assay and agarose gel electrophoresis, respectively. 
Our group, and other researchers, have observed that bacteria is inefficient in producing full-
length HMGB1 protein due to the long stretch of repeating glutamic and aspartic acid residues 
present in the acidic C-terminal tail domain [199]. Therefore, recombinant HMGB1 purified 
from E. coli usually consists of a mixture of full-length and C-tail truncated HMGB1 proteins. 
While partial loss of the C-terminal tail can be visualized using SDS-PAGE gel electrophoresis, 
smaller differences in the protein sequence can only be assessed by mass spectrometry analysis. 
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For the experiments included in Paper III, we used the different HMGB1 proteins (full-length 
HMGB1, full C-tail truncated HMGB1 and partially C-tail truncated HMGB1) to investigate 
the effect of the tail domain on the interaction with TLR2. C-tail domain is believed to control 
access to the DNA binding boxes of HMGB1 [200]. Therefore, it is important to analyze the 
output of the protein production. 
I will conclude this section with a brief discussion about the most important factor that 
influences HMGB1 function: the redox state of the cysteine residues. After the HMGB1 protein 
is purified, additional tests must be performed to examine the biological activity of the 
synthesized protein. To determine the cytokine-inducing activity of our recombinant proteins, 
we measured pro-inflammatory cytokine production (e.g. TNF) after addition to peripheral 
blood mononuclear cells (PBMCs). To generate the fully reduced HMGB1 protein, we add a 
redox reagent, dithiothreitol (DTT), to the purification buffers. E. coli expresses a periplasmic 
enzyme that is required for catalyzing disulfide bonds [201]. However, production of disulfide 
HMGB1 remains challenging.  
 
4.2 IN VITRO EXPERIMENTS  
My thesis work was also heavily based on in vitro experiments: immortal cell lines (Papers I 
and III), primary PBMC cultures (Paper III) and enzymatic reactions in Eppendorf tubes (Paper 
II).  
Immortal cell lines come from tumorous cells or cells with artificially introduced mutations in 
order to proliferate indefinitely. The most commonly used and oldest example of such a cell 
line are HeLa cells derived from cervical cancer cells of a deceased patient in 1951 [202]. 
Possibility of culturing a homogenous cell population over several generations is the major 
reason for choosing immortal cell lines over primary cells in the scientific studies. In addition, 
there are more advantages of immortalized cell lines. Standard well-characterized lines help to 
obtain reproducible results and bypass ethical concerns associated with the use of animal and 
human tissue. Thus, they are a common thread in experimental research performed in labs 
worldwide. The main goal in selecting appropriate methodology for Paper I was to create an 
optimized well-controlled system for systematic comparison of cell death modes. THP-1 is a 
spontaneously immortalized cell line isolated from the peripheral blood of a child suffering 
from acute monocytic leukemia and can be cultured for about 3 months without changes of cell 
sensitivity and activity [203, 204]. Although THP-1 cell became the gold standard for studying 
immune responses of monocytes and macrophages, it also has downsides [204]. While the use 
of cultured THP-1 cells as a model for primary human monocytes ex vivo constitutes the basic 
concept of translational research, multiple studies show significant differences between them 
[205]. THP-1 is a monocyte-like cell line and should not be confused with monocytes as 
immortalized cell lines can express unique gene patterns not found in any cell type in vivo. On 
the other hand, once the cells are differentiated to macrophages, they express similar markers 
to PBMCs. Another issue is the spontaneous mutation leading to THP-1 cell immortalization 
that could affect responses to induction of different cell death modes in my experiments. In 
order to overcome this issue, doses of death inducing agents were optimized (Paper I, data not 
shown). Lastly, immortalized cells are studied in a controlled setting that is different from their 
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natural complex environment. Therefore, it is desirable to compare the results with experiments 
in primary cells before drawing strong conclusions.  
Another advantage is a possibility of creating a cell line expressing a gene of interest. This was 
the basis of choosing human embryonic kidney cell line (HEK293) as experimental model in 
Paper III. HEK293 cells are widely used in cell biology research due to high success rate of 
transfection. In order to scrutinize the relationship between HMGB1 and its receptor TLR2, 
HEK293 were transfected either only with TLR2 or along TLR1/TLR6. Depending on the 
stimulant, TLR2 forms heterocomplexes with TLR1and TLR6. Utilizing three separate 
systems based on the same cell line can provide specific information about the ligand. On the 
other hand, such a straightforward approach creates a risk of oversimplification of complex 
cellular processes. Therefore, we also performed experiments in a mouse alveolar macrophage 
(MH-S) cell line, which expressed all TLRs and the CD36 receptor important for TLR2 
activation [206, 207]. 
Lastly, the lack of positive results in the cell lines lead us to perform experiments in more 
complex primary systems, PBMCs and whole blood of healthy volunteers (Paper II). Primary 
cultures are formed by culturing cells directly obtained from blood or tissue biopsy. PBMCs 
are isolated from peripheral blood and consist of lymphocytes, monocytes, natural killer 
cells and dendritic cells. Thus, PBMCs are the major cells in human immunity. While the 
frequencies of cell populations differ between donors and even can be vary in same donor on 
different days due changes in the donor’s physiological status, consistency of results obtained 
from separate donors strengthens the scientific observation. One drawback in using PBMCs in 
our studies is their skew towards the adaptive immunity. Lymphocytes are the dominating cell 
population in PBMCs while cells of the innate immune system we focus our studies on 
constitute only up to 20% of the collected cells. Another drawback of primary cells is short life 
span of the cultures. It is not possible to culture PBMCs over several passages. As researchers 
most often need to work on freshly isolated cells, the number of donors and extracted blood 
volume create limiting factors in experiments. Similar issues apply to whole blood assays, 
where freshly collected blood is stimulated and cultured ex vivo. Although cells are not 
separated in such assay, they might respond to the environmental change by losing their 
structural and functional characteristics.  
In summary, cell lines provide an elegant system to study detailed immune reactions and 
understand processes taking place in more complex settings. However, one should always 
verify the results in a native primary cell setting. It is crucial to select the appropriate 
experimental system and think about readouts.  
 
4.3 EXPERIMENTAL ANIMAL MODELS 
Animal models of human disease provide a practical tool for studying disease-driving immune 
reactions in vivo. They also constitute an important step towards translation of basic research 
into human disease and help to predict the outlook for novel therapeutic targets. On the other 
hand, there are many drawbacks and ethical controversies regarding use of animals in research. 
Most of the animal models represent only one or several symptoms of a condition but do not 
address the complete human disease pathogenesis. Therefore, the researcher needs to specify 
which aspect of the disease is the study focus before selecting an animal model. Moreover, the 
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study results need to be validated in different pre-clinical disease models before clinical trials 
could be allowed. Even such a stringent approach is not guaranteeing success in human therapy. 
Unfortunately, many therapies show promising results in experimental models but fail in 
clinical trials [208]. Another major concern regarding animal use in research is ensuring their 
ethical use in studies. In order to support animal welfare, the “three Rs” rule was introduced in 
1959: Replacement, Reduction and Refinement [209]. This rule was followed in the study 
design for evaluation of a humanized, chimeric anti-HMGB1 antibody effects in DILI (Paper 
IV).  
Replacement 
Efforts are made to avoid animal testing and use in vitro models. While traditional cell culture 
models fail to predict hepatotoxicity of the tested drugs, the novel 3D culturing systems could 
be a solution for pharmacological studies [210]. However, our study focus was not on the drug 
hepatoxicity but the HMGB1-mediated inflammation. Liver tissue culture models do not reflect 
the role of the immune system in DILI development. As there was no replacement possibility 
in order to carry out a pre-clinical study, we chose to utilize the standard dose-dependent mouse 
model of DILI with well-characterized involvement of HMGB1. 
Reduction 
Our strategy was to use the minimum number of animals needed for statistical power in results 
analysis. Unfortunately, this approach forced us to reduce the quality of life of the experimental 
animals by fasting them 15 hours prior to APAP challenge. Putting the mice in such metabolic 
state allowed us to reduce inter-subject variation and see stronger effect in DILI, and thus 
reduce the number of animals needed to obtain sufficient data to answer our research question. 
Another way to minimize the number of experimental animals is to maximize the information 
obtained per study object. We analyzed liver and blood for established biomarkers of DILI and 
the presence of inflammatory mediators.  
Refinement 
We chose the acute model of DILI with respect to animal welfare. Staff at Karolinska animal 
facility ensured the animal quality of life and independently evaluated whether the 
experimental procedures aimed to minimize pain and distress.  
In summary, we chose an experimental mouse model of DILI with already described HMGB1-
mediated inflammation. APAP-induced liver toxicity in mice is a straightforward approach for 
pre-clinical evaluation of HMGB1-blocking therapies and does not harm animal welfare.  
 
4.4 CLINICAL SAMPLES 
While my thesis work focused on the mechanisms of HMGB1 signaling in inflammatory 
conditions in general, it also involved examination of human samples. My research group, 
together with the Pediatric Rheumatology division at Karolinska University Hospital, has 
established a biobank of JIA patients’ samples, which include serum and synovial fluid (SF). 
While many assays in research facilities and clinics are optimized for plasma and serum 
measurements, only a few are compatible with SF. This is due to the very viscous physical state 
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of SF and the limited sample volume that can be obtained from patients only during a disease 
flare.  
For the study described in Paper II, I selected SF samples with complete clinical data and 
characterized isoforms of HMGB1 [124]. The samples contained high total levels of HMGB1 
with chemotactic and a cytokine-inducing function. Additionally, monomethylation of lysine 
43 of the protein indicated that the HMGB1 present in the sample originated from neutrophils 
[124]. Therefore, those samples were suitable material for investigating the effect of neutrophil 
enzymes (elastase and cathepsin G) and other disease-associated enzymes present in the joint 
(matrix metalloproteinase 3) on the pathogenic extracellular HMGB1.  
The SF samples were chosen to study HMGB1-regulating processes at the local site of 
inflammation. However, one cannot extrapolate the results to the pathogenesis of JIA. The 
sample size was small and heterogenous with regard to JIA sub-diagnosis and treatment. In 
addition, the sample selection did not follow the 2:1 female-to-male patient ratio apparent in 
the clinic.  
 
4.5 DETECTION AND QUANTIFICATION OF HMGB1 
 
In order to allow for a proper comparison and to increase the reproducibility of the findings, 
it was that we had a reliable HMGB1 detection method. The HMGB1 ELISA developed by 
Shino-Test Corporation was first introduced onto the market approximately 10 years ago and 
it is regarded as the gold-standard assay for measuring HMGB1 in both cells supernatants 
and biological samples [211]. Therefore, I chose to use this assay as the primary detection 
method for measuring total HMGB1 levels throughout my thesis work. While it is preferable 
to use a standard detection assay, it is important to remember that every method has also its 
limitations. As mentioned in the introductory chapters of this book, HMGB1 forms 
complexes with other DAMPs and immune mediators. Although the epitope for the antibody 
used in the HMGB1 ELISA is confidential, it is most probably located within/close to box B 
of the protein. We noticed that recombinant box A is undetectable in the assay (unpublished 
data). It is also possible that molecules bound to HMGB1 interfere with HMGB1 detection 
in biological samples due to epitope masking [212, 213].  
 
In addition to using the commercial ELISA, I have also used western blotting analysis, 
another standard method for protein detection, to measure HMGB1. Most of the epitopes of 
the antibodies used in these experiments are known. Detecting HMGB1 with antibodies 
against both the N- and C-terminal domains is superior over ELISA as it confirms presence 
of full-length protein. In contrast, the Shino-Test ELISA does not distinguish between full-
length and truncated protein. Using western blotting analysis with multiple anti-HMGB1 
antibodies allowed us to map the different peptides formed after enzymatic cleavage of 
HMGB1 (Paper II). However, the technique also has its drawbacks as it requires a relatively 
high concentration of HMGB1 in small sample volume and assay optimization for each 
individual antibody. 
 
While the abovementioned methods are useful for measuring total HMGB1 levels, they do 
not detect PTMs, and thus it is not possible to distinguish between the different redox 
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isoforms or identify hyperacetylated protein using this assay.s To date, mass spectrometry is 
the only technology that allows such analysis. During my PhD studies, LC-MS/MS was used 
for characterization of targeted PTMs. The output of this technique was area under the curve 
(AUC) values for specific peptides, which allowed identification of redox isoforms and 
hyperacetylation of NLS2 in a qualitative manner. However, access to this method is very 
limited. As HMGB1 is a major player driving the pathogenesis of multiple inflammatory 
diseases, efforts should be made to develop a straightforward and high throughput technique 
to measure the different functional isoforms of HMGB1.  
 
4.6 MAPPING PROTEASE CLEAVAGE SITES IN HMGB1 
I separated the peptide/protease mixture on a SDS-PAGE gel in order to identify peptides 
resulting from HMGB1 proteolytic cleavage (Paper II). The standard Tris/glycine gels 4-20% 
gradient gels were used for that purpose. I expect I would have obtained an improved 
resolution of small peptides if I used Tris/tricine gels, which slow down the migration rates 
of peptide-SDS complexes. On the other hand, I was primarily interested in the initial 
products of the proteolytic cleavage and Tris/glysine gels were sufficient for the separation. 
The samples were investigated by western blotting as described above. In addition, selected 
gel bands containing HMGB1 peptides were analyzed by mass spectrometry, nanoLC-
MS/MS. This method allowed identification of peptide sequences. However, the method 
required in-gel trypsin digestion of the fragments in question. Trypsin preferentially cleaved 
peptides on the C-terminal side of lysine and arginine amino acid residues. High number of 
these residues in HMGB1 sequence (over 20%) made it difficult to identify the exact protease 
cleavage sites. Therefore, we could only confirm the coverage of peptides detected with SDS-
PAGE and western blotting using this method. Mass spectrometry assay that could analyze 
the peptides without enzymatic digestion would be preferred. Alternatively, an enzyme with 
fewer cleavage sites within HMGB1 sequence could be chosen for in-gel digestion of the 
protein fragments. 
A higher resolution of the peptide/protease mixture could also be obtained by 2D gel 
electrophoresis. The method could be successful due to the dipolar nature of HMGB1 [214]. 
The negatively charged aspartate and glutamate amino acid repeats make the C-terminal tail 
domain prone to protonation at low pH [215]. The separated differentially charged peptides 
could be then analyzed by mass spectrometry. 
Published literature and specialized online tools were helpful with identification of the 
predicted cleavage sites. We used PROSPER (https://prosper.erc.monash.edu.au/), a webserver 
for in silico prediction of protease substrate in order to speculate about the cleavage sites. 
However, the protease cleavage sites predicted by the abovementioned methods would require 
further verification. Site-directed mutagenesis of specific residues could confirm the expected 
cleavage sites. 
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5 RESULTS AND DISCUSSION 
 
5.1 HMGB1 IN INFLAMMATION: REGULATION OF HMGB1 RELEASE FROM 
THE IMMUNE CELL 
As a prototypical DAMP, extracellular HMGB1 is associated with stress or injury in the body 
[106]. Multiple studies have reported that circulating HMGB1 is a result of immune cell 
activation and cell death. However, it has never been shown in a well-controlled manner how 
a single immune cell contributes to the extracellular levels of HMGB1 under different 
physiological conditions. Therefore, we decided to induce different modes of cell death in vitro 
in THP-1 monocyte-like cells; a cell line that is commonly used to study functions of human 
monocytes and macrophages.  
In Paper I, we confirmed that pure apoptosis does not lead to HMGB1 release while necrosis 
results in a passive release of intranuclear HMGB1. Other types of immunogenic cell death 
also result in HMGB1 release, although to a lesser extent. Our results suggest that dying cells 
release HMGB1 with different kinetics. Alamin release happens in a controlled manner unless 
cells become necrotic. In addition to measuring the extent of HMGB1 release during different 
physiological conditions, we looked at other markers of cellular immunogenicity. While the 
release of the cytosolic enzyme LDH and alarmin HMGB1 without active production of pro-
inflammatory cytokines during necrosis was expected from previous studies, interesting 
information about immunogenicity of different cell death modes could be derived from other 
experimental conditions [106]. 
Cell populations maintain homeostasis by removing aged and impaired cells from tissues by 
homeostatic mechanisms of apoptosis. We activated intrinsic pathways of apoptosis by two 
different inducers: the clinically relevant topoisomerase II inhibitor, Etoposide, and an 
unspecific prototypical ATP-competitive kinase inhibitor, Staurosporine (STS). Subsequently, 
we monitored apoptosis induction for up to 24 hours by analysis of activation of apoptotic 
effector caspases and cellular membrane permeability. Extracellular HMGB1 was detected 
only after membrane disintegration, as confirmed by LDH release. Being the homeostatic type 
of cell death, apoptosis was neither associated with release of cytosolic components nor 
secretion of pro-inflammatory molecules. Our data confirmed that STS is a potent inducer of 
apoptosis displaying a more rapid kinetics than topoisomerase II inhibition. However, cells 
released LDH and HMGB1 even before the peak of the apoptotic effector caspase activity. 
Lack of TNF and IL-1β in the supernatant suggests that the cells underwent secondary necrosis. 
No pro-inflammatory molecules were detected in Etoposide-induced apoptosis, which suggest 
successful formation of apoptotic bodies and further supports use of Etoposide as cancer drug 
in the clinics. This result complements our earlier study, where patients suffering from 
macrophage activation syndrome treated with Etoposide showed reduced levels of systemic 
HMGB1. Detected HMGB1 was only in the sulfonyl redox form in contrast to the fully reduced 
and disulfide HMGB1 isoforms present in serum before the treatment [216]. 
Lack of ATP hinders caspase activity and prevents cells from undergoing apoptosis. If cells are 
simultaneously subjected to stress, the intracellular processes lead to the activation of 
necroptotic pathways. Necroptosis is a cell death type, which serves as an intrinsic host defense 
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against viral infection. This cell death mode is also associated with certain ischemic conditions. 
Metabolism in cells is affected by the oxygen shortage resulting from the restricted blood 
supply. Limited energy supplies impede function of caspases that normally signal towards 
homeostatic apoptosis. When the distressed cells sense an additional stressing factor, such as 
acute-phase pro-inflammatory cytokine TNF, they activate receptor-interacting protein kinase 
1 (RIPK1) and RIPK3 that lead to JNK activation, ROS production and the induction of 
necroptosis. I induced necroptosis by blocking apoptotic caspase cascades and stimulating cells 
with LPS, a potent inducer of TNF transcription. We then followed the release of HMGB1 for 
24h in a kinetic manner and noticed the slight increase of HMGB1 levels 18 hours after 
necroptosis induction. Interestingly, Necrostatin 1(Nec-1), a potent inhibitor of RIPK1, did not 
affect the alarmin release. High dose of LPS caused constant release of TNF and likely 
subsequent activation of the cell death receptor, TNFR1. However, there was no difference in 
the readouts upon blocking RIPK1 with its allosteric inhibitor Nec-1. This compound was 
originally discovered as a blocker of necrotic cell death in human and murine cells [49]. In the 
initial optimization experiments, Nec-1 reduced cytoxicity associated with necroptosis (data 
not shown). Since the Nec-1 effect on cytotoxicity could not be replicated in the study described 
in Paper I, Nec-1 inhibition of cytotoxicity would require further verification. In addition, 
experiments using other and more stable specific RIPK1 inhibitors might explain the poor 
effects of Nec-1 [217]. 
While HMGB1 release from pyroptotic cells was reported before, the exact release mechanism 
has never been clarified in relation to the activated inflammasome. We noticed that HMGB1 
was released from stimulated PMA-differentiated THP-1 cells independently of NLRP3-
inflammasome-dependent pyroptosis. The two-hit system for inflammasome activation with 
LPS and nigericin, a bacterial-derived potassium ionophore, was needed to induce IL-1β 
production associated with NLRP3 inflammasome but not necessary for HMGB1 induction. 
The high sensitivity of cells was likely caused by PMA differentiation. There is a possibility 
that HMGB1 would only be released from the pyroptotic cells after a longer post-differentiation 
resting period. LPS and nigericin as well as nigericin alone caused high release of cytosolic 
LDH. Thus, nigericin not only induced formation and activation of the NLRP3 inflammasome 
but also induced cell death.  
Cellular activation in the pyroptosis experiments inspired us to further investigate HMGB1 
release from the challenged cells. We decided to take a step back and use undifferentiated cells 
in order to assess their ability to secrete HMGB1 upon activation. THP-1 cells stimulated with 
100 ng/ml LPS produced induced secretion of approximately 40 ng/ml HMGB1 after 24 hours. 
However, LDH release and low level of IL-1β in the supernatant indicated ongoing cell death, 
possibly pyroptosis. Interestingly, co-stimulation with IFNγ did not affect neither HMGB1 
release nor the cytotoxicity. Our results suggest that immunogenic cell death pathways such as 
necrosis and pyroptosis produce more extracellular HMGB1 than the monocyte-like cells 
activated with LPS + IFNγ. 
Surprisingly, no HMGB1 was detected in the NETs of neutrophils undergoing NETosis. 
Previous report showed that neutrophils carried HMGB1 predominantly in the cytoplasm 
instead of nucleaus, which was associated with methylation of lysine at position 42 of HMGB1 
[218]. The PTM within box A possibly weakened HMGB1 binding to DNA. As NETs were 
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primarily composed of DNA, HMGB1’s absence could be expected. I could speculate that 
HMGB1 would be released by activated neutrophils before they proceed to NETosis. HMGB1 
that remained in the cell would also be released during NETosis but would not attach to the 
NETs.  
 
5.2 EXTRACELLULAR HMGB1 AT THE SITE OF INFLAMMATION 
After demonstrating that HMGB1 is released from the monocytic cells into the extracellular 
space though multiple mechanisms (Paper I), we decided to follow the fate of the alarmin 
(Paper II and Paper III).  
5.2.1 Proteolytic processing of HMGB1: new regulatory mechanism 
While pro-inflammatory signaling is necessary for the activation of defense and repair systems, 
the downregulatory mechanisms should operate in concert to limit result in acute inflammation. 
Extracellular HMGB1 is present not only during the acute immune response but also during 
dysregulated chronic inflammation, for example in the synovial fluid of arthritis patients. 
Therefore, we designed a study to investigate HMGB1 regulation at the site of inflammation 
(Paper II). Previous study showed that mast cells, abundantly present in synovium, secrete 
chymase, serine peptidase stored in their secretory granules, to degrade HMGB1 and other 
alarmins [92, 219, 220]. Our study further explored the potential effect of synovial 
endopeptidases on HMGB1. Neutrophils are found in high numbers in the inflamed rheumatic 
joints and undergo degranulation to secrete proteases upon activation. Serine proteases such as 
Human Neutrophil Elastase (HNE), Cathepsin G (CG) and proteinase 3 (PR3) are the major 
group of endopeptidases abundantly secreted by those cells to the synovial fluid. Liberated 
enzymes are important regulators of inflammation due to their ability to process multiple 
chemokines, cytokines and cell surface receptors in order to activate or deactivate them. For 
example, HNE and PR3 cleave the precursor of TNF to its mature form. Both HMGB1 and 
neutrophils are found in synovial fluid of arthritis patients. We thus speculated that neutrophil 
serine proteases could affect the pro-inflammatory features of the released alarmin.   
We studied the published literature and utilized PROSPER software for in silico prediction of 
protease substrates and their cleavage sites to identify whether HMGB1 was a substrate of HNE 
and CG. We confirmed the presence HNE and CG in synovial fluid of JIA patients at average 
levels of 278.1 ng/ml and 60.2 pg/ml, respectively. After performing an initial optimization 
and screening, we saw a consistent cleavage pattern of HMGB1 by HNE in SDS-PAGE. Initial 
cleavage lead to the formation of a peptide with molecular weight close to the one of the full-
length protein. We hypothesized that such proteolytic cleavage could potentially lead to the 
formation of HMGB1 fragments with altered features. Multiple studies with recombinant 
peptides suggest that box B of HMGB1 alone can act as pro-inflammatory agent while box A 
can act as an HMGB1 antagonist. However, no reports exist that could confirm the presence of 
such fragments in vivo. Western blotting and mass spectrometry analysis indicated an initial 
and gradual truncation of the C-terminus tail of HMGB1 upon HNE processing. Based on the 
prediction model, we also suspected that HMGB1 could be cleaved at the N-terminus later in 
the process. While the loss of the acidic C-terminal tail could expose the receptor binding sites 
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within HMGB1, N-terminal cleavage could also serve as a regulatory switch. Most proteolytic 
events that activate members of the IL-1 cytokine family and multiple chemokines take place 
within a limited region at the N-terminus. Partial protein degradation could also result in 
improved accessibility of receptor binding sites and thereby improve the binding of HMGB1 
to its receptors. The C-terminal tail domain was previously reported to make extensive contacts 
with the DNA-binding surfaces of both HMG boxes [221]. One could speculate that only this 
initial cleavage of HMGB1 by HNE might take place in vivo as the proteomic analysis of the 
synovial fluid of RA patients reveled upregulation of HNE inhibitory complex [222]. 
On the contrary, it was not possible to identify any fragments of HMGB1 after its processing 
by CG. At molar ratio 1:80 CG completely degraded HMGB1 within 5 minutes. Hence, we 
concluded that CG inhibits pro-inflammatory activities of HMGB1 by protein disintegration. 
This result strongly suggests that the CG’s proteolytic cleavage is a novel mechanism of 
HMGB1 clearance at the local site of inflammation during arthritis. However, CG levels did 
not correlate with HMGB1 in the synovial fluid of JIA patients. Due to the lack of direct 
relationship between CG and HMGB1 in the patients’ samples and identified broad spectrum 
of CG substrates, CG might not be a promising therapeutic agent for HMGB1 downregulation. 
It is also unclear whether redox and acetylation of HMGB1 affect proteolytic regulation. We 
used recombinant HMGB1 while the endogenous HMGB1 in JIA patients had different PTMs 
[124].  Nevertheless, our results provide an insight into endogenous clearance of HMGB1 by 
activated neutrophils at the inflammatory site. 
In addition to studying the neutrophil serine proteases’ activity on extracellular HMGB1, we 
also examined whether other arthritis-associated enzymes could process the alarmin. Matrix 
metalloproteinase 3 (MMP-3) is a cysteine endoprotease driving the cartilage degradation in 
arthritis. MMP-3, expressed in synovial tissue by endothelial cells and fibroblasts, is 
upregulated both in synovial fluid and tissue of RA patients [223]. Moreover, clinical studies 
indicate a direct correlation between MMP-3 serum levels and the progression of joint 
destruction in patients with early RA [224, 225]. MMP-3 was detected in all SF samples at 
significantly higher levels than serine proteases, with an average of 31.5 µg/ml. Similar to 
HNE, MMP-3 cleaved HMGB1 at the C-terminal tail. We analyzed two peptide products of 
the MMP-3 cleavage by WB and MS (fragment I and fragment II in Fig. 4 of Paper II). 
Although the fragments differed in size on the SDS-PAGE and WB, the cleavage mapping 
assays showed identical results. Both C-terminal tail and its linker region were missing in the 
examined fragments. Therefore, we proposed that the higher molecular weight peptide 
(fragment I, Fig. 4, Paper II) consisted of both box A and box B. Such fragment could retain 
the pro-inflammatory activities of the full-length HMGB1. As it is not possible for a lower 
molecular weight fragment to have exactly the same sequence, we suggest that fragment II in 
Fig. 4 of Paper II is actually a mixture of two peptides of equal molecular weight. It is difficult 
to speculate about the possible functions of such peptides. It is, however, apparent that both 
HMGB1 fragments contain amino acids 89-109, the minimal sequence needed for cytokine 
activity. 
Our results were based on HMGB1 produced in E. coli, which is a common system of protein 
expression and usually results in high and homogenous protein yields. However, the results 
should be verified in studies with mammalian expressed HMGB1, for example Chinese 
Hamster Ovary (CHO) cells. It was shown that only HMGB1 expressed CHO cells had 
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glycosyl modification [199]. Therefore, a possibility exists that there are other PTMs in 
mammalian expressed HMGB1 that could not be retained in the bacterial system. PTMs could 
affect the affinity of the proteases to their cleavage sites. As discussed earlier, the actively 
secreted HMGB1 at the inflammation site is hyperacetylated at its NLSs. In order to strengthen 
our findings about proteolytic regulation, experiments should be reproduced in acetylated 
HMGB1.  
In conclusion, we were able to identify a novel mechanism of HMGB1 regulation at the local 
site of inflammation by demonstrating the rapid degradation of the alarmin by and removal of 
the C-terminal tail domain by HNE and MMP-3. Protein truncation could liberate functional 
fragments of HMGB1 that were shown to exhibit either pro- or anti-inflammatory functions as 
recombinant peptides in the previous in vitro studies. It is not known whether PTMs of HMGB1 
could affect the proteolytic regulation.  
5.2.2 Understanding HMGB1 interaction with its receptor TLR2 
Although we never cloned and expressed any of the predicted enzymatic cleavage products, 
we received a recombinant HMGB1 truncated at the C-terminal tail as a “gift” from bacteria 
during the protein production. Our lab and others noticed that truncated protein is a common 
by-product of HMGB1 production in E. coli when N-terminal tags are used for protein 
purification [226, 227]. We decided to investigate whether the protein truncation could affect 
the receptor binding ability of HMGB1.  
TLRs are key components of the innate immune response. Several members of the TLR family 
have been reported to interact with HMGB1 including the transmembrane receptors TLR2, 
TLR4 and TLR5 [119, 137, 228]. Previous studies reported that the C-terminal tail presence is 
dispensable for TLR4 binding but essential for activating TLR5-mediated pro-inflammation 
[119, 137]. Conflicting data in the literature exists regarding HMGB1 binding with TLR2 and 
no data exists pointing towards HMGB1 structure as a factor in this interaction [119, 135, 229, 
230]. Therefore, we set up a study to clarify the opposing results regarding the receptor binding 
and investigate whether protein truncation at C-terminal tail could affect the interaction. We 
specifically focused on the cytokine-inducing function of HMGB1 as the expected result of its 
interaction with TLR2. 
Firstly, we tested if the different protein constructs bound to TLR2 in a plate-based assay, where 
we coated the wells with HMGB1 or C-terminal tail truncated HMGB1 (Δ30). The truncated 
HMGB1 form bound to TLR2-Fc in a dose dependent manner, while the full-length HMGB1 
protein did not interact with the receptor. Interestingly, partial loss of the C-terminal tail, which 
is a common result of HMGB1 protein production, also showed binding to TLR2. This initial 
result suggested that the C-terminal tail inhibited the interaction with TLR2. As such, we 
wanted to investigate whether the Δ30 binding with TLR2 could have a functional outcome. 
HMGB1 interactions with different TLRs had been previously tested in HEK293 cells that 
were selectively transfected with individual receptors. HEK293 cells expressing TLR2 and 
stimulated with full-length HMGB1 showed NF-κB-induced secreted embryonic alkaline 
phosphatase (SEAP) upregulation [137]. However, TLR2 is known to form heterodimers with 
TLR1 or TLR6 in order to enable differential recognition of lipopeptides [231]. We therefore 
set up an in vitro system with HEK293 cells transfected with TLR2 alone, TLR2 and TLR1 or 
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TLR2 and TLR6. We stimulated cells with full-length HMGB1 and Δ30 as well as the known 
ligands of the receptor heterocomplexes, PGN and Pam3CSK4. Surprisingly, neither of the 
HMGB1 ligands induced IL-8 production in any of the HEK293 cell lines. This is in contrast 
to previous report showing HMGB1 interaction with TLR2 RAW264.7 macrophages by 
fluorescence resonance energy transfer. [135] 
TLRs often require co-receptors for a proper reaction to sensed danger. CD36 is a glycoprotein 
found in lipid rafts of the cell membrane. It has been shown that CD36 enhances immune 
responses to some TLR2–TLR6 ligands [232]. Thus, we decided to preform analogous 
experiments in cells which highly express CD36, the mouse alveolar macrophage cell line MH-
S. Again, neither HMGB1 nor Δ30 induced pro-inflammatory cytokine production. Finally, we 
confirmed the lack of functional outcome of interaction between C-tail truncated HMGB1 and 
TLR2 in the whole blood system. 
Extracellular HMGB1 can form complexes with TLRs’ ligands such as LPS and DNA. Our 
lab has previously demonstrated that HMGB1 is able to interact with Pam3CSK4 to enhance 
its pro-inflammatory activity [141, 144]. Thus, we decided to investigate whether HMGB1 
enhances PGN-induced cytokine production via TLR2. We let the full-length HMGB1 and Δ30 
pre-form complexes with PGN before we stimulated PBMC to discover that both protein 
complexes induced cytokine production dose-dependently and at similar levels. These 
comparable results suggest that the binding site(s) for PGN and TLR2 are located within the 
HMG boxes or the linker residues.  
In summary, we purified HMGB1 lacking the C-terminal tail and confirmed its binding to 
TLR2 in vitro. However, we could not record cytokine induction as the result of the interaction. 
Both the full-length and truncated HMGB1 proteins formed complexes with the TLR2 ligand, 
PGN, and enhanced cytokine production in PBMCs. The C-terminal tail truncated HMGB1 
could be a result of HMGB1 regulation by endopeptidases as explained in Paper II. The gradual 
truncation of the C-terminal tail by enzymatic cleavage could promote HMGB1/TLR2 
interaction in vivo. 
 
5.3 ANTI-HMGB1 THERAPY: FROM BASICS TO CLINIC 
Understanding release and regulation of HMGB1 is important for establishing it as a 
therapeutic target. While HMGB1 biology is complex, blocking the total levels of extracellular 
HMGB1 might be beneficial for the patients suffering from inflammatory conditions. 
Therefore, we decided to make a step towards anti-HMGB1 therapy by designing a new clinical 
tool.   
5.3.1 Developing h2G7 as a new therapeutic tool  
Monoclonal antibodies (mAbs), i.e. epitope-specific antibodies produced from a single B-
lymphocyte clone, gained the attention of pharmaceutical industry quite fast after their 
generation. The technology was developed in 1975 and led to the approval of the first murine 
therapeutic antibody OKT3 (muromonab) as a treatment of kidney transplant rejection ten 
years later [233, 234]. To date, more than 40 mAbs have been approved by the U.S. Food and 
Drug Administration as effective therapy in different diseases, for example the TNF-blocking 
  39 
mAb, infliximab, for treatment of RA [235]. Furthermore, around 300 mAbs are currently in 
clinical testing and at the current approval rate around 70 monoclonal antibody products will 
be on the market by 2020 [236]. While the pre-clinical testing of therapeutic mAbs showed 
promising results, the clinical tests revealed few shortcomings. The human immune system 
recognizes proteins from different species as foreign. Thus, the patient’s immune system 
eliminates the murine antibody in the human anti-mouse antibody (HAMA) response [237, 
238]. Besides the short serum half-life, murine mAbs often fail to trigger human effector 
functions. Since the first mAb was approved in therapy, the advancing antibody engineering 
techniques have resulted in reduction of immunogenicity and the HAMA response. Chimeric 
antibodies were developed by replacing the constant domains of the mouse antibody with 
human sequences [239]. As the chimeric antibodies are approximately 70% human, they are 
not readily cleared by the patient’s immune system. Moreover, humanized antibodies were 
developed which have an even stronger human backbone than the chimeric antibodies, where 
only the antigen-binding site in the variable region of the humanized antibody originates from 
mouse. 
Monoclonal antibody 2G7 was produced by fusing spleen cells from immunized mice with 
myeloma cells. It showed promising results in multiple disease models of inflammation of both 
sterile and infectious origin. Our research group and collaborators have showed that mouse 
2G7 (m2G7) reduced the clinical signs in mouse models of arthritis and DILI [133, 192]. We 
decided to make the 2G7 antibody more suitable for clinical use by applying rational methods 
of antibody humanization [240]. We generated a human chimeric 2G7 antibody (h2G7) by 
hybridization with human IgG1, a common feature of clinically approved therapeutic 
antibodies (Paper IV). The IgG1 backbone does not affect the antibody’s mechanism of action 
and permits both the antibody-dependent cell-mediated cytotoxic (ADCC) activity and the 
complement-dependent cytotoxic (CDC) activity. We confirmed antibody specificity using in 
vitro studies and the affinity by surface plasmon resonance (SPR). In order to verify that m2G7 
mode of action was retained in h2G7, we took a rational approach of creating and testing 
effector function‐deficient variants of h2G7 incapable of binding complement or Fc receptors 
(FcRs). Our approach is described in the Materials and Methods section of Paper IV.   
5.3.2 HMGB1 blockade in pre-clinical model of DILI 
After we successfully created a potential new therapeutic tool for HMGB1 neutralization, we 
decided to test its therapeutic properties. In order to facilitate anti-HMGB1 therapy with h2G7 
in the clinics, we set out to test h2G7 in a known pre-clinical disease model and compare its 
activity to the original mouse antibody.  
The major role of HMGB1 as a pro-inflammatory mediator in DILI pathogenesis was explained 
in the previous chapters. The therapeutic efficiency of m2G7 in APAP-induced hepatic 
inflammation, a common type of DILI, was shown before [106, 241]. Thus, we decided to use 
this disease model to verify that the humanization had no negative effect on the therapeutic 
efficiency. We successfully induced DILI in mice as demonstrated in Figure 2 of Paper IV 
(PBS group). Both m2G7 and h2G7 displayed similar therapeutic effects in APAP-challenged 
mice. While there was only limited protection from the liver injury itself, the post-injury hepatic 
inflammation was suppressed. Prevention of the HMGB1-mediated propagation of 
inflammation is a desirable therapeutic outcome in DILI since the post-injury hepatic 
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inflammation negatively correlates to clinical outcome of APAP overdose patients.  The strong 
effect on the inflammatory aspect of DILI pathogenesis with little or no effect on the hepatic 
injury, suggests 2G7 blocks HMGB1-induced cytokine production and immune cell 
infiltration.  
In conclusion, we created a chimeric monoclonal antibody that blocks total levels of HMGB1 
and prevents post-injury inflammation in mouse DILI. The antibody is partially humanized 
and, according to experiments with mutant versions of the mAb, most likely acts through 
HMGB1 neutralization, which could prevent HAMA and other adverse effects in patients. 
However, more detailed studies on antibody effects are needed before h2G7 could be tested in 
chronic complex diseases.  
 
 
 
 
 
 
 
 
 
 
Figure 7. Summary of the main results.  
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6 CONCLUDING REMARKS 
 
In conclusion, my PhD work expanded the knowledge regarding extracellular HMGB1, its 
function and regulation during inflammation. I studied the release of HMGB1 from a 
monocytic cell line, THP-1, investigated its processing by inflammation-associated 
endopeptidases, clarified interactions with its receptor, TLR2, and developed partially 
humanized monoclonal antibody against HMGB1 that could be a successful therapy in pre-
clinical DILI. The specific conclusions are listed below: 
 
Immunogenic cell death modes are major contributors of extracellular HMGB1 
Our results confirmed that cells undergoing controlled apoptosis do not release HMGB1 unless 
the apoptotic process proceeds to an autolytic necrotic outcome. High cytotoxicity and 
HMGB1 release without production/release of other inflammatory markers indicated that 
necrosis is associated with passive release of nuclear fully reduced HMGB1, as previously 
reported [116]. Pyroptosis is another immunogenic cell death type associated with high 
HMGB1 release. Both DAMPs and pro-inflammatory cytokines are produced by pyroptotic 
cells, which indicates active secretion of HMGB1. Necroptosis is also associated with HMGB1 
release, although at a slower rate. Although HMGB1 does not form NETs of human neutrophils 
undergoing NETosis, I speculate that activated neutrophils release HMGB1 upon activation 
and/or that HMGB1 is released during NETosis but detaches from DNA. Methylation of lysine 
42 in box A of HMGB1 found in synovial fluid of arthritis patients suggests its neutrophil 
origin.  
 
Extracellular HMGB1 is a novel substrate for the inflammation-associated proteases: 
HNE, CG and MMP-3 
Neutrophils are immune cells recruited to the sites of inflammation, where they contribute to 
propagation of inflammation and tissue damage. Our group has previously shown that 
neutrophils are major source of extracellular HMGB1 found in synovial fluids of JIA patients 
[124]. My PhD work now suggests that besides releasing the alarmin, activated neutrophils 
might be involved in regulation of HMGB1 activity via proteases released from their 
azurophilic granules. A possible outcome is downregulation of HMGB1 and formation of 
functional peptides. HMGB1 is also a substrate for a highly abundant tissue-degrading protease 
in synovium, MMP-3. It was previously shown that the levels of HMGB1 and MMP-3 correlate 
in synovial fluid of JIA patients [185]. Such correlation strengthens the hypothesis that MMP 
-3 cleaves HMGB1 at the site of inflammation. The initial cleavage of HNE and MMP-3 occurs 
at the acidic C-terminus.  
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The C-terminal tail domain of HMGB1 regulates TLR2 binding 
While the purified full-length HMGB1 is not a ligand of TLR2, the C-terminal tail truncation 
enables the receptor binding. Therefore, the epitope for TLR2 binding is within HMG boxes or 
the linker region of HMGB1, and can be masked by the C-terminal tail. However, we could 
not detect any cytokine production as a result of HMGB1 interaction with TLR2. 
Both the full-length and C-terminal tail truncated HMGB1 formed pro-inflammatory 
complexes with PGN, a known ligand of TLR2. Therefore, we hypothesized that truncated 
HMGB1 formed after proteolytic cleavage (e.g. by HNE or MMP-3) could enhance TLR2-
mediated inflammatory activities. In fact, earlier reports showing HMGB1-mediated induction 
of cytokine production via TLR2 could actually be due to endotoxin impurities in recombinant 
protein preps. 
The results from Paper II and Paper III suggest a novel mechanism that could affect HMGB1 
extracellular functions. Proteolytic cleavage of HMGB1 might lead to higher affinity of 
HMGB1 to its receptors. Therefore, proteases can enhance pro-inflammatory functions of 
HMGB1. On the other hand, there is also a possibility of anti-inflammatory outcome of the 
proteolytic cleavage by exposing box A of the protein, HMGB1 antagonist, or by complete 
protein degradation. 
 
A novel humanized anti-HMGB1 antibody serves as a successful therapy in pre-clinical 
DILI 
A mAb against HMGB1, 2G7, has shown therapeutic effects in animal models of human 
diseases. As many mAbs are produced in mice, human-anti mouse antibody responses are a 
significant problem in the clinics. We made a step towards designing 2G7-based patient 
treatment by the antibody humanization. In order to confirm therapeutic properties of the novel 
chimeric antibody, we compared its performance along with the original 2G7 in a mouse model 
of DILI. Both antibodies successfully blocked hepatic post-injury inflammation. The antibody 
performance was neither dependent on complement nor Fc mediated cytotoxicity. Therefore, 
we concluded that the h2G7 mAb had therapeutic value and its mode of action of 2G7 was 
HMGB1 neutralization.  
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7 FUTURE PERSPECTIVES 
 
While my PhD work expanded on previous knowledge about the activity of extracellular 
HMGB1 during inflammatory conditions, it also created new questions. 
 
Is immunogenic cell death the major source of the extracellular HMGB1? 
My data suggest that immunogenic cell death is the major producer of the extracellular 
HMGB1 and that the released levels exceed the amounts of HMGB1 secreted by the activated 
cells. These results should be verified in other in vitro systems; especially in cells where the 
activity of JAK-STAT signaling pathway, associated with active release of HMGB1, is 
validated. In order to maintain the controlled conditions, comparisons could be made with 
experiments on the macrophage-like differentiated THP-1 cells before a more challenging 
verification in PBMCs.  
The next important step needed for understanding the role of cell death in inflammation would 
be to identify which functional redox isoforms of HMGB1 are released. It is known that 
necrotic HMGB1 has thiol adducts at all three cysteine residues. Thus, necrotic HMGB1 
promotes leukocyte recruitment to the site of inflammation. The redox state of HMGB1 
released after pyroptosis is believed to be in the highly pro-inflammatory disulfide form. Thus, 
lower total HMGB1 levels during pyroptosis do not mean that pyroptosis is less immunogenic 
than necrosis. Our quantitative analysis should be followed by a qualitative study in order to 
have a more complete picture of HMGB1 extracellular activity at the site of inflammation. It 
would also be interesting to follow the isoform formation in a kinetic manner to understand 
whether the fate of HMGB1 is determined within the cell or formed as a net effect of the factors 
in the extracellular milieu. The qualitative analysis is currently only possible with mass 
spectrometry, an expensive and laborious technique. Due to high costs and limited availability 
of the mass spectrometry, an indirect analysis could be performed based on in vitro assays, 
where cells in homeostasis are stimulated with the supernatants from dying cells. While such 
analysis could only suggest but not determine HMGB1 redox isoforms, it could provide more 
insight into the impact of cell death on healthy tissue. 
 
What is the outcome of proteolytic regulation of HMGB1 the site of inflammation? 
Redox regulation has been a hot topic in HMGB1 research for the past few years. However, 
other regulatory mechanisms for HMGB1 activity exist and contribute to HMGB1 activity 
during inflammation. My PhD work pointed towards proteases as a novel endogenous 
regulatory mechanism of HMGB1 activity at the local site of inflammation. In order to 
understand the effect of inflammation-associated endopeptidases HNE, CG and MMP-3 on 
HMGB1, the predicted peptides formed after proteolytic cleavage could be synthesized. The 
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HMGB1 fragments could be then tested in functional assays, such as in vitro stimulation of 
macrophage cell cultures. It would also be interesting to test different redox isoforms of these 
peptides by oxidizing them with H2O2 and reducing with DTT. In addition, my data in 
combination with a previous report from our lab suggests an interesting feedback loop 
mechanism in which activated neutrophils downregulate the HMGB1 that they release [124]. 
Therefore, more efforts should be made to study neutrophils found in the synovial fluid of JIA 
patients. I believe that my initial results could open a new direction in studying extracellular 
HMGB1 regulation and more inflammation-associated endopeptidases should be studied as 
potential regulators of HMGB1, e.g. PR3 expressed not only in the primary granules but also 
on the cellular membrane of neutrophils.  
JIA is a heterogeneous disease. Analyses of higher number of patient samples and/or 
stratification od samples according to patients sub-diagnosis could reveal potential correlation 
between levels of HMGB1 and endoproteases. More insight into HMGB1 regulation at the site 
of inflammation could also be derived from levels of protease inhibitory complexes, such as 
alpha1 protease inhibitor and alpha2 macroglobulin. 
Our studies showed that C-terminal tail truncated HMGB1 is a ligand of TLR2. Unfortunately, 
we could not detect functional outcome of this interaction. This is in contrast to some previous 
studies suggesting a pro-inflammatory effect of the receptor interaction. For example, HMGB1 
signaling through TLR2 on myeloid dendritic cells resulted in an effective anti-glioblastoma 
immune response [242]. It is possible that the interaction is cell-type dependent and that more 
factors are involved in the signaling in vivo that could be elucidated from controlled in vitro 
experiments with highly purified HMGB1.  
 
Is HMGB1 blockade a promising therapy for inflammatory diseases? 
Lastly, we created and tested a novel therapeutic tool for HMGB1 blockade: a partially 
humanized mAb specific for HMGB1. The antibody performed well in a pre-clinical mouse 
model of DILI by inhibiting post-injury hepatic inflammation. Thus, it can serve as a basis for 
further development of a clinical HMGB1-specific treatment option. HMGB1 is a late mediator 
of lethal systemic inflammation compared to TNF and IL-1 [241, 243]. Therefore, HMGB1 
blockade could open a new therapeutic window for treatment of inflammatory conditions.  
On the other hand, multiple studies have reported a protective role for the fully reduced 
HMGB1 for. It has important functions in wound healing, muscle regeneration and repair of 
multiple tissues. Therefore, creating a therapeutic tool targeting only the disulfide isoform of 
HMGB1 would be an idealanti-HMGB1 therapy. 
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